<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005944</article-id><article-id pub-id-type="pmc">PMC11861728</article-id><article-id pub-id-type="doi">10.3390/vetsci12020183</article-id><article-id pub-id-type="publisher-id">vetsci-12-00183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Individualized Pooled CRISPR/Cas9 Screenings Identify CDK2 as a Druggable Vulnerability in a Canine Mammary Carcinoma Patient</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4862-984X</contrib-id><name><surname>Inglebert</surname><given-names>Marine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vetsci-12-00183" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00183" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9404-7122</contrib-id><name><surname>Dettwiler</surname><given-names>Martina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-vetsci-12-00183" ref-type="aff">1</xref><xref rid="af3-vetsci-12-00183" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Chang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vetsci-12-00183" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00183" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7780-8233</contrib-id><name><surname>Markkanen</surname><given-names>Enni</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af4-vetsci-12-00183" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7945-6737</contrib-id><name><surname>Opitz</surname><given-names>Lennart</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af5-vetsci-12-00183" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9509-485X</contrib-id><name><surname>Naguleswaran</surname><given-names>Arunasalam</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-vetsci-12-00183" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2044-9844</contrib-id><name><surname>Rottenberg</surname><given-names>Sven</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00183" ref-type="aff">1</xref><xref rid="af6-vetsci-12-00183" ref-type="aff">6</xref><xref rid="af7-vetsci-12-00183" ref-type="aff">7</xref><xref rid="c1-vetsci-12-00183" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Dodds</surname><given-names>W. Jean</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00183"><label>1</label>Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland; <email>inglebert.marine@gmail.com</email> (M.I.); <email>info@vetscope.com</email> (M.D.); <email>chang.he@unibe.ch</email> (C.H.); <email>arunasalam.naguleswaran@unibe.ch</email> (A.N.)</aff><aff id="af2-vetsci-12-00183"><label>2</label>Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland</aff><aff id="af3-vetsci-12-00183"><label>3</label>Vetscope Pathologie Dettwiler, L&#x000f6;rracherstrasse 50, 4125 Riehen, Switzerland</aff><aff id="af4-vetsci-12-00183"><label>4</label>Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Z&#x000fc;rich, 8056 Z&#x000fc;rich, Switzerland; <email>enni.markkanen@vetpharm.uzh.ch</email></aff><aff id="af5-vetsci-12-00183"><label>5</label>Functional Genomics Center Zurich, University of Z&#x000fc;rich and ETH, 8092 Z&#x000fc;rich, Switzerland; <email>lopitz@fgcz.ethz.ch</email></aff><aff id="af6-vetsci-12-00183"><label>6</label>Bern Center for Precision Medicine, University of Bern, 3012 Bern, Switzerland</aff><aff id="af7-vetsci-12-00183"><label>7</label>Cancer Therapy Resistance Cluster, Department for BioMedical Research, University of Bern, 3012 Bern, Switzerland</aff><author-notes><corresp id="c1-vetsci-12-00183"><label>*</label>Correspondence: <email>sven.rottenberg@unibe.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>183</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>This study explores the potential of canine patient-derived organoids (PDOs) in identifying mammary tumor-specific weaknesses by comparing tumor cells with matching normal mammary PDOs from the same patient. For this purpose, two customized CRISPR/Cas9 screens were performed to identify genes that are essential for tumor cells to survive but dispensable for normal mammary epithelial cells. CDK2 was subsequently identified as an important vulnerability in PDOs derived from a canine mammary tumor patient, which can be targeted by an existing inhibitor, PF3600. Although we only used tumors and normal PDOs from a single patient, our approach exemplifies how to discover novel, more individualized anti-cancer treatments for dogs.</p></abstract><abstract><title>Abstract</title><p>High-throughput omics approaches have long been used to uncover potential vulnerabilities in human personalized oncology but are often limited by the lack of functional validation. Therefore, we placed our emphasis on functional drug testing using patient-derived organoids (PDOs). However, PDOs generated from tumors mostly lack comparison with matching normal tissue, and the number of testable drugs is limited. Here, we demonstrate how matching the neoplastic and non-neoplastic mammary PDOs derived from the same dog can utilize targeted CRISPR/Cas9 screens to unveil cancer cell specific vulnerabilities. We performed two independent CRISPR/Cas9 dropout screens using sub-libraries targeting the epigenome (<italic toggle="yes">n</italic> = 1269) or druggable genes (<italic toggle="yes">n</italic> = 834) in paired PDOs derived from both carcinoma and normal mammary tissues from the same dog. A comparison of essential genes for tumor cells survival identified CDK2 as a functional vulnerability in canine mammary tumors (CMTs) that can be targeted with the PF3600 inhibitor. Additional potential targets were also uncovered, providing insights for personalized cancer treatments in dogs.</p></abstract><kwd-group><kwd>gene-editing tools</kwd><kwd>mammary tumor</kwd><kwd>patient-derived organoid (PDO)</kwd><kwd>epigenome</kwd><kwd>druggable gene</kwd><kwd>precision medicine</kwd></kwd-group><funding-group><award-group><funding-source>Swiss National Science Foundation</funding-source><award-id>310030_179360</award-id></award-group><funding-statement>Financial support for this study came from the Swiss National Science Foundation (310030_179360 to S.R.).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00183"><title>1. Introduction</title><p>Canine mammary tumors (CMTs) rank second among the most frequent tumors in predominantly older, female dogs [<xref rid="B1-vetsci-12-00183" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00183" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00183" ref-type="bibr">3</xref>]. About half of the CMTs are malignant and display highly heterogenous histological subtypes [<xref rid="B4-vetsci-12-00183" ref-type="bibr">4</xref>]. They mainly arise from epithelial cells, but some also involve myoepithelial cells (complex tumors) or mesenchymal cells (mixed tumors). Pure mesenchymal or myoepithelial tumors rarely occur [<xref rid="B5-vetsci-12-00183" ref-type="bibr">5</xref>]. Frequently, multiple CMTs of different histological subtypes can occur in various mammary complexes of the same patient [<xref rid="B6-vetsci-12-00183" ref-type="bibr">6</xref>]. Due to shared key clinicopathologic features, dogs are considered to be a potential spontaneous cancer model for human breast cancer (HBC) in translational oncology [<xref rid="B7-vetsci-12-00183" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00183" ref-type="bibr">8</xref>]. Furthermore, mutations in the PI3K-Akt pathway are a frequent finding in both species. However, one of the main challenges in HBC research remains in the identification of biomarkers that can efficiently predict patients&#x02019; therapy responses [<xref rid="B9-vetsci-12-00183" ref-type="bibr">9</xref>]. Additionally, there are species-specific molecular mechanisms, such as, for example, fewer <italic toggle="yes">TP53</italic> mutations in CMT compared to HBC and a lower tumor mutational burden [<xref rid="B10-vetsci-12-00183" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>,<xref rid="B12-vetsci-12-00183" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00183" ref-type="bibr">13</xref>]. Furthermore, while the finding may be specific to the cohort analyzed, whole genome sequencing (WGS) analysis performed on a cohort of 21 malignant CMTs suggested that characteristic HBC mutational signatures of HBC, such as those resulting from defects in APOBEC cytidine deaminases or homologous recombination repair deficiency [<xref rid="B14-vetsci-12-00183" ref-type="bibr">14</xref>], do not appear to play a significant role in CMT carcinogenesis [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>]. Instead, age-related deamination of methyl cytosines seems to be the dominant genotype. While CMTs are lower in their tumor mutational burden, their phenotypic heterogeneity suggests epigenetic or post-translational modifications to play a role, which could potentially explain the co-evolution of complex carcinomas with myoepithelial involvement [<xref rid="B15-vetsci-12-00183" ref-type="bibr">15</xref>].</p><p>In veterinary medicine, surgery remains the treatment of choice for CMTs, and the determination of biomarkers, such as hormone receptors, is not routinely performed in the clinic. Currently, those biomarkers are mainly used as prognostic indicators for research purposes [<xref rid="B16-vetsci-12-00183" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-12-00183" ref-type="bibr">17</xref>], and no study links them to therapy response. This is mostly because chemotherapy often does not provide a clear advantage for dogs suffering from CMTs [<xref rid="B5-vetsci-12-00183" ref-type="bibr">5</xref>], and clinical studies are limited. For patients suffering from metastatic diseases, treatment options are often unsuccessful. Therefore, more efforts are needed to develop targeted therapies in canine patients. This requires solid preclinical studies to increase our understanding of CMT carcinogenesis and to identify therapeutic vulnerabilities.</p><p>For this purpose, we have previously generated models for patient-derived organoids (PDOs) from CMTs that accurately recapitulate the morphology, hormone receptor status, and genetic characteristics of their tissues of origin while maintaining disease heterogeneity [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>]. In particular, CMT organoids derived from the malignant and non-neoplastic mammary epithelial tissues from the same patient can be established and expanded long-term [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>]. One helpful approach to understanding tumorigenesis is identifying and characterizing genes that are essential (&#x0201c;essentialome&#x0201d;) for tumor cells to survive but are dispensable for normal cells. Those genes that are essential in tumor cells but not in normal tissues may be useful therapeutic targets with high tumor cell-specific effectiveness and minimal side effects (the concept of synthetic lethality) [<xref rid="B18-vetsci-12-00183" ref-type="bibr">18</xref>]. We previously demonstrated that CMT organoids can be used as an ex vivo tool for studying mutation mechanisms with CRISPR/Cas9 [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>]. CRISPR/Cas9 libraries of many different individual perturbations, i.e., each single-guide RNA (sgRNA), offer high throughput screening possibilities to understand specific tumor behaviors [<xref rid="B19-vetsci-12-00183" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-12-00183" ref-type="bibr">20</xref>]. Those libraries can be genome-wide or designed to study a selection of genes of interest or one specific pathway [<xref rid="B21-vetsci-12-00183" ref-type="bibr">21</xref>]. They can be used to develop novel therapeutic targets [<xref rid="B22-vetsci-12-00183" ref-type="bibr">22</xref>], but to our knowledge no CRISPR/Cas9 dropout screen compared a cancer cell line to its matched non-neoplastic tissue derived from the same patient. Using organoids, a genome-wide CRISPR/Cas9 screen in induced pluripotent stem cell-derived kidney organoids has been successfully performed [<xref rid="B23-vetsci-12-00183" ref-type="bibr">23</xref>]. For PDOs, however, scaling up is challenging, and the number of cells to reach the appropriate library coverage (i.e., the number of cells having one single sgRNA) is difficult to obtain [<xref rid="B24-vetsci-12-00183" ref-type="bibr">24</xref>]. In this context, the use of targeted libraries simplifies experimental setups. This technique has been applied to patient-derived colon organoids, where a custom pan-cancer tumor suppressor gene CRISPR library has been generated to identify tumor drivers [<xref rid="B25-vetsci-12-00183" ref-type="bibr">25</xref>].</p><p>In this study, we functionally identified the druggable vulnerabilities of CMTs using two independent pooled CRISPR/Cas9 dropout screening approaches for PDOs from both the carcinoma and non-neoplastic mammary tissues from an individual canine patient. Using this approach, we support the basic concept of unraveling specific predictive markers and guide treatment options for individual patients based on differential functional genetic screening using matched PDOs from neoplastic versus non-neoplastic tissues.</p></sec><sec id="sec2-vetsci-12-00183"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00183"><title>2.1. Sample Collection and Tissue Processing</title><p>We previously generated a living biobank of CMTs and non-neoplastic mammary tissue from client-owned donor dogs [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>]. Briefly, surplus mammary tissue from dogs undergoing standard mastectomy due to spontaneous CMTs were obtained in collaboration with small animal veterinary clinics throughout Switzerland between 2018 and 2020. All procedures followed standard care veterinary guidelines and relevant Swiss regulations and ethical standards. Informed consent was obtained for each sample in accordance with the ARRIVE guidelines (<uri xlink:href="https://arriveguidelines.org/">https://arriveguidelines.org/</uri> accessed on 22 September 2022) when applicable. Ethical approval was granted by the Cantonal Veterinary Office. Additional EDTA blood for DNA isolation was collected with approval by the &#x0201c;Cantonal Committee for Animal Experiments&#x0201d; (Canton of Bern; permit 71/19).</p><p>Half of the CMTs were formalin-fixed paraffin-embedded (FFPE) while the remaining tissues were minced and cryopreserved using a freezing medium (10% DMSO, 45% Dulbecco&#x02019;s Modified Eagle Medium, 45% Fetal Calf Serum (Thermo Fisher Scientific, Waltham, MA, USA)). Randomly selected pieces were snap-frozen and stored at &#x02212;80 &#x000b0;C for RNA isolation.</p></sec><sec id="sec2dot2-vetsci-12-00183"><title>2.2. Histology</title><p>Hematoxylin and eosin (H&#x00026;E)-stained FFPE sections of primary tumors were analyzed by a board-certified veterinary pathologist (M.D.). Primary tumors were classified and graded according to the commonly accepted Davis&#x02013;Thompson classification and grading system [<xref rid="B15-vetsci-12-00183" ref-type="bibr">15</xref>,<xref rid="B17-vetsci-12-00183" ref-type="bibr">17</xref>].</p></sec><sec id="sec2dot3-vetsci-12-00183"><title>2.3. Maintenance of CMT Organoid Cultures</title><p>Using our previously established biobank of canine mammary tumors, we selected two organoid lines derived from both normal and cancerous tissue with known long-term culture stability for this study. Both PDOs were derived from the same treatment-naive 9-year-old intact female Cocker Spaniel, which underwent radical unilateral mastectomy due to multiple benign and malignant mammary neoplasms. ORG-63-C was derived from a nodule histopathologically diagnosed as a complex carcinoma while adjacent grossly non-neoplastic glandular tissue was used to derive ORG-63-N [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>].</p><p>Frozen organoids were thawed, rinsed, and the pellet was resuspended in cold CMT organoid medium [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>] and mixed at a 1:1 ratio with Cultrex<sup>&#x000ae;</sup> PathClear Reduced Growth Factors Basement Membrane Extract (BME) Type 2 (Amsbio, Abingdon, UK). The BME-cell suspension was seeded as 30 &#x000b5;L drops on prewarmed 24-wells suspension culture plates (Greiner Bio-One, Kremsm&#x000fc;nster, Austria) and cultured following standard protocols [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>,<xref rid="B26-vetsci-12-00183" ref-type="bibr">26</xref>] to expand the organoids.</p></sec><sec id="sec2dot4-vetsci-12-00183"><title>2.4. Lentivirus Production, Lentiviral Transduction</title><p>Lentivirus was produced using standard protocols [<xref rid="B27-vetsci-12-00183" ref-type="bibr">27</xref>] by delivering pLentiCRISPRv2 vectors loaded with the custom sub-libraries and lentiviral packaging plasmids. Transduction of the organoids was performed according to previous protocols [<xref rid="B28-vetsci-12-00183" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot5-vetsci-12-00183"><title>2.5. Pooled CRISPR/Cas9 Screening</title><p>Both lentiviral-based CRISPR/Cas9 sub-libraries were designed using the canine CanFam3.1 assembly. Sub-library CP1736 contains 6004 sgRNAs, targeting 834 &#x0201c;druggable&#x0201d; genes with known inhibitors (six sgRNAs per gene) along with 500 non-targeting and intergenic controls each (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S2</xref>). Sub-library CP1737 contains 8614 sgRNAs, targeting 1269 epigenetic regulatory genes (six sgRNAs per gene) with 500 non-targeting and intergenic controls (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S1</xref>). For each screen, sixteen million ORG-63-C and ORG-63-N were collected and transduced with lentivirus at a multiplicity of infection (number of viral particles per cell) of four. The medium was replaced with a puromycin-containing medium (3.5 &#x000b5;g/mL, GIBCO) 24 h later, and selection was performed for eleven days. Twelve days after transduction (day 0 = D0), organoids were trypsinized, a pool of cells isolated for D0 (at least 3 million), and we seeded the rest of the cells into two technical replicates (R1, R2) with a coverage of 500 cells per sgRNA (at least 3 million cells per replicate). We passaged the organoids every ten days and harvested them after ten doubling times, hence after forty days (D40). DNA was extracted from the D0 and D40 population and sent for sequencing. The sgRNAs that were differentially enriched or depleted after 40 days compared to the pDNA were identified with the MAGeCK software version 0.5 [<xref rid="B29-vetsci-12-00183" ref-type="bibr">29</xref>]. For PCR amplification, gDNA was divided into 100&#x02009;&#x003bc;L reactions such that each well had at most 10&#x02009;&#x003bc;g of gDNA.</p><p>For each 96-well plate, the PCR master mix was prepared by combining 150 &#x003bc;L of DNA Polymerase (Titanium Taq; Takara, Kusatsu, Japan), 1 mL of 10&#x000d7; buffer, 800 &#x003bc;L of dNTPs (Takara), 50 &#x003bc;L of P5 stagger primer mix (AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT[s]TTGTGGAAAGGACGAAAC*A*C*C*G, where [s] represents the barcode region, 100&#x02009;&#x003bc;M), and the remaining volume was adjusted to 4 mL with water. Each well contained 50&#x02009;&#x003bc;L of gDNA plus water, 40&#x02009;&#x003bc;L of PCR master mix, and 10&#x02009;&#x003bc;L of a uniquely barcoded P7 primer (CAAGCAGAAGACGGCATACGAGAT[s]GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCAATTCCCACTCCTTTCAAG*A*C*C*T, where [s] is the barcode region, 5&#x02009;&#x003bc;M). The PCR cycling conditions were as follows: (1) 95 &#x000b0;C for 1 min; (2) 94 &#x000b0;C for 30 s; (3) 52.5 &#x000b0;C for 30 s; (4) 72 &#x000b0;C for 30 s; (5) go to (2), 27 cycles; (6) 72 &#x000b0;C for 10 min. PCR products were purified using Agencourt AMPure XP SPRI beads, following the manufacturer&#x02019;s protocol (Beckman Coulter, Beverly, MA, USA A63880). Samples were sequenced on a HiSeq2500 High Output (Illumina, Ipswich, MA, USA)) with a 5% PhiX spike-in. Enrichment analysis was performed using MAGeCK (Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout) [<xref rid="B29-vetsci-12-00183" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot6-vetsci-12-00183"><title>2.6. Proliferation Assay</title><p>Organoids were dissociated into single cells, and 35,000 cells were seeded per well in 10 &#x000b5;L BME/CMT medium drops on a 24-wells plate. Every day, proliferation was assessed using the resazurin-based Cell Titer Blue following the manufacturer&#x02019;s instructions (Promega, Madison, WI, USA). In brief, 25 &#x000b5;L of the reagent was added to the culture medium and incubated for 4 h at 37 &#x000b0;C. 200 &#x000b5;L of the medium was then pipetted to a 96-wells plate, and fluorescence intensity at 560Ex/590Em nm was determined with an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The mean and standard deviation of three different wells was calculated. Two technical replicates were performed.</p></sec><sec id="sec2dot7-vetsci-12-00183"><title>2.7. Drug Testing and Cell Viability Assays</title><p>Per well in a 24-well plate, a droplet of 10 &#x000b5;L single-cell-suspension containing 35,000 dissociated organoid cells with BME and medium was seeded. After polymerization of the BME/medium droplet, medium infused with various concentrations of PF-06873600 (AdipoGen Life Sciences, F&#x000fc;llinsdorf, Switzerland), doxorubicin (Teva Pharma AG, Basel, Switzerland), reversine R3904 (Sigma Aldrich, St. Louis, MO, USA), and luminespib NVP-AUY922 (Selleckchem, Houston, TX, USA) was added to the well without disrupting the droplet. The growth medium containing doxorubicin was replaced with a drug-free medium after 24 h, while the medium was refreshed after 72 h of incubation for the remaining treatments. After six days of incubation, cell viability was assessed using a resazurin-based dye (Cell Titer Blue, Promega) in at least two biological replicates per treatment. Untreated controls were used for normalization, and IC50 values were determined by fitting cell growth data to a four-parameter logistic sigmoidal curve.</p></sec><sec id="sec2dot8-vetsci-12-00183"><title>2.8. RNA Isolation and Sequencing of the Primary Tumors and Non-Neoplastic Mammary Tissues</title><p>Sample and library preparation: The list of tissues sequenced can be found in <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S7</xref>. In total, RNA from 34 carcinomas and 17 non-neoplastic mammary tissues were isolated from snap-frozen samples stored at &#x02212;80 &#x000b0;C using the RNeasy mini kit (Qiagen, Hilden, Germany) following the manufacturer&#x02019;s instructions. RNA sequencing was performed at the Novogene company. RNA degradation and contamination were monitored on 1% agarose gels. RNA purity was checked using the NanoPhotometer<sup>&#x000ae;</sup> spectrophotometer (IMPLEN, Westlake Village, CA, USA). RNA integrity and quantitation were assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, USA). A total amount of 1 &#x000b5;g RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext<sup>&#x000ae;</sup> Ultra&#x02122; RNA Library Prep Kit for Illumina<sup>&#x000ae;</sup> (NEB, Ipswich, MA, USA) following the manufacturer&#x02019;s recommendations, and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under an elevated temperature in NEBNext First Strand Synthesis Reaction Buffer (5X) or by using sonication with Diagenode Bioruptor Pico for breaking RNA strands. First-strand cDNA was synthesized using a random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-). Second strand cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H. Remaining overhangs were converted into blunt ends via exonuclease/polymerase activities. After adenylation of 3&#x02032; ends of DNA fragments, NEBNext Adaptor with hairpin loop structure was ligated to prepare for hybridization. To select cDNA fragments of preferentially 150&#x02013;200 bp in length, the library fragments were purified with the AMPure XP system (Beckman Coulter, Beverly, MA, USA). Then, 3 &#x000b5;L USER Enzyme (NEB, USA) was used with size-selected, adaptor-ligated cDNA at 37 &#x000b0;C for 15 min, followed by 5 min at 95 &#x000b0;C before PCR. Then, PCR was performed with Phusion High-Fidelity DNA polymerase, Universal PCR primers, and Index (X) Primer. At last, PCR products were purified (AMPure XP system), and library quality was assessed on the Agilent Bioanalyzer 2100 system. Then, the clustering of the index-coded samples was performed on a cBot Cluster Generation System using PE Cluster Kit cBot-HS (Illumina) according to the manufacturer&#x02019;s instructions. After cluster generation, the library preparations were sequenced on an Illumina platform, and paired-end reads were generated.</p><p>Data analysis: Raw data (raw reads) of FASTQ format were firstly processed using fastp (Version 0.20) [<xref rid="B30-vetsci-12-00183" ref-type="bibr">30</xref>]. For the downstream analysis, adapter content, poly-N sequences, and low-quality reads were removed to generate clean reads, and Q20, Q30, and GC content were calculated. Reference genome and gene annotation files were retrieved from genome browsers, such as NCBI, UCSC, or Ensembl. The paired-end clean reads were then aligned to the reference genome using HISAT2 software v2.0.5. The mapped reads of each sample were assembled by StringTie (vl.3.3b) [<xref rid="B31-vetsci-12-00183" ref-type="bibr">31</xref>]. The featureCounts vl.5.0-p3 program was used to count the reads numbers mapped to each gene. FPKM (expected number of Fragments Per Kilo base of transcript sequence per Millions base pairs sequenced of each gene) was calculated based on the length of the gene and reads count mapped to this gene. Before differential gene expression analysis, for each sequenced library, the read counts were adjusted by Trimmed Mean of M-values through one scaling normalized factor. Then, differential expression analysis was performed using the edgeR R package (3.22.5). The <italic toggle="yes">p</italic>-values were adjusted using the Benjamini&#x02013;Hochberg method. The corrected <italic toggle="yes">p</italic>-value of 0.05 and absolute fold change of 2 were set as the threshold for significantly differential expression.</p><p>Enrichment analysis: Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by the clusterProfiler R package, correcting gene length bias. GO terms with corrected <italic toggle="yes">p</italic>-value less than 0.05 were considered significantly enriched by differential expressed genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway enrichment analysis was performed by the clusterProfiler R package to test the statistical enrichment of differential expression genes.</p></sec><sec id="sec2dot9-vetsci-12-00183"><title>2.9. RNA Sequencing of the Organoids (Paired Carcinoma and Non-Neoplastic Mammary Tissue)</title><p>Sample and library preparation: Organoids were trypsinized, and RNA was extracted using the RNeasy mini kit (Qiagen) following the manufacturer&#x02019;s instructions. The quality of the isolated RNA was determined with a Fragment Analyzer (Agilent, Santa Clara, CA, USA). Only the samples with a 260 nm/280 nm ratio between 1.8 and 2.1 and a 28S/18S ratio within 1.5&#x02013;2 were further processed. The TruSeq Stranded mRNA (Illumina, Inc., San Diego, CA, USA) was used in the succeeding steps. Briefly, total RNA samples (100&#x02013;1000 ng) were poly-A enriched and then reverse-transcribed into double-stranded cDNA. The cDNA samples were fragmented, end-repaired, and adenylated before ligation of TruSeq adapters containing unique dual indices for multiplexing. Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and quantity of the enriched libraries were validated using the Fragment Analyzer (Agilent, Santa Clara, CA, USA). The product is a smear with an average fragment size of approximately 260 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20. The NovaSeq 6000 (Illumina, Inc, San Diego, CA, USA) was used for cluster generation and sequencing according to standard protocol. The sequencing mode was a single end with 100 bp.</p><p>Data analysis: The raw reads were first cleaned by removing adapter sequences, trimming low-quality ends, and filtering reads with low quality (phred quality &#x0003c; 20) using fastp (Version 0.20) [<xref rid="B30-vetsci-12-00183" ref-type="bibr">30</xref>]. Sequence pseudo alignment of the resulting high-quality reads to the reference genome (build CanFam3.1, gene models based on Ensembl release 104 downloaded on 1 June 2021) and quantification of gene-level expression was carried out using Kallisto (Version 0.46.1) [<xref rid="B32-vetsci-12-00183" ref-type="bibr">32</xref>].</p><p>When comparing RNA sequencing data from primary tissues and organoids, the raw reads were cleaned by removing adapter sequences, trimming low-quality ends, and filtering low-quality reads using tools available in the Galaxy platforms (usegalaxy.org and usegalaxy.org.au). Subsequently, reads were mapped to the canine genome (Canis_lupus_familiaris.ROS_Cfam_1.0.dna.toplevel) using the bowtie2 tool with default parameters. Mapped reads counts to protein-coding transcripts were extracted from the BAM file based on the gene annotations from the Canis_lupus_familiaris.ROS_Cfam_1.0.107.gff3 file using the featureCounts tool. To detect differentially expressed genes, we applied a count-based negative binomial model implemented in the software package DESeq2 (R version: 4.2.0, DESeq2 version: 1.36.0) [<xref rid="B33-vetsci-12-00183" ref-type="bibr">33</xref>]. Genes showing altered expression with an adjusted (Benjamini&#x02013;Hochberg method) <italic toggle="yes">p</italic>-value &#x0003c; 0.05 were considered differentially expressed.</p></sec><sec id="sec2dot10-vetsci-12-00183"><title>2.10. Statistical Analysis and Data Representation</title><p>Statistical analyses and data representation were mainly performed using Prism statistical software (v9.0; GraphPad Inc, San Diego, CA, USA). Statistical tests and <italic toggle="yes">p</italic>-values are indicated in the text or the figures&#x02019; legends. Parts of some figures were created with BioRender.com and Inkscape (RRID: SCR_014479). The heatmaps of <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figures S3 and S4</xref> were designed with Morpheus (<uri xlink:href="https://software.broadinstitute.org/morpheus">https://software.broadinstitute.org/morpheus</uri> accessed on 22 September 2022).</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00183"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00183"><title>3.1. Design and Lentiviral Transduction of Two Custom Canine CRISPR/Cas9 Libraries to Identify Therapeutic Vulnerabilities in CMTs</title><p>To assess which genes are essential in mammary tumor cells but not in adjacent normal mammary tissues, we used two organoid (ORG) lines from the same patient, called dog 63 (ORG-63-N, derived from non-neoplastic mammary tissue and ORG-63-C, derived from a mammary carcinoma). We transduced those two organoid lines with different customized canine CRISPR/Cas9 sub-libraries following standard guidelines for sgRNA optimization (<xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>a) [<xref rid="B34-vetsci-12-00183" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-12-00183" ref-type="bibr">35</xref>]. Since we did not observe many genetic alterations in CMTs that would explain tumorigenesis [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>], we hypothesized that epigenetic alterations might play a crucial role in the formation of CMTs. Therefore, we designed the first custom library to target canine genes that may be essential for the epigenetic regulation of tumors but not normal mammary epithelial cells. This canine &#x0201c;epigenome&#x0201d; library (CP1737) contains 8614 sgRNAs, targeting 1269 genes (six sgRNAs/gene, see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S1</xref>), of which the human homologs have previously been linked to epigenetic processes [<xref rid="B35-vetsci-12-00183" ref-type="bibr">35</xref>,<xref rid="B36-vetsci-12-00183" ref-type="bibr">36</xref>,<xref rid="B37-vetsci-12-00183" ref-type="bibr">37</xref>]. We cloned this library into the lentiCRISPRv2 one vector system containing Cas9 (pXPR_023). Moreover, as many genes involved in epigenetic regulation do not have known inhibitors, and as our main aim was to find concrete new treatment options for CMTs, we designed a second custom library that targets &#x0201c;druggable&#x0201d; genes, i.e., with known inhibitors existing. The &#x0201c;druggable&#x0201d; library (CP1736) contains 6004 sgRNAs, targeting 834 canine genes (six sgRNAs/gene, see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S2</xref>), of which the human or mouse homologs have been described to be druggable by already existing compounds [<xref rid="B35-vetsci-12-00183" ref-type="bibr">35</xref>,<xref rid="B38-vetsci-12-00183" ref-type="bibr">38</xref>,<xref rid="B39-vetsci-12-00183" ref-type="bibr">39</xref>]. We also cloned this library into the lentiCRISPRv2 one vector system containing Cas9 (pXPR_023).</p><p>For both independent screening experiments, we aimed to express the library in CMT-derived organoids at a coverage of 500 cells per sgRNA. After twelve days of puromycin selection (necessary for the organoids to recover from the transduction and survive the following trypsinization), all read counts at D0 were higher than for the original plasmid DNA (pDNA) in both screens, indicating that the PCR reaction worked efficiently (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S1a,b</xref>). Importantly, we reached the 500x coverage of the libraries we aimed to obtain. After splitting the organoids into single cells at D0, we seeded two technical replicates (R1, R2) of the screen with a coverage of 500 cells per sgRNA. We passaged the organoids every ten days and harvested them after ten doubling times, i.e., after forty days (D40). Both cell lines show similar proliferation rates in vitro (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S1c</xref>). DNA was extracted from the D0 and D40 population and sent for sequencing. The sgRNAs that were differentially enriched or depleted after 40 days compared to the pDNA were identified with the MAGeCK software [<xref rid="B29-vetsci-12-00183" ref-type="bibr">29</xref>].</p><p>The quality of the two screens was further assessed by principal component analysis and calculating the Pearson correlation of the different samples to each other, based on the normalized read counts of all samples (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S1d&#x02013;g</xref>). When we carried out a principal component analysis to compare the samples, we observed that the D0 samples cluster was very close to the pDNA. By contrast, the technical replicates at D40 (R1, R2) of ORG-63-N and ORG-63-C cluster to each other, indicating that our analysis is reproducible for both screens (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S1d,e</xref>). In addition, the technical replicates at D40 of ORG-63-N and ORG-63-C were highly correlated for both screens, strengthening the reproducibility of our analysis (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S1f,g</xref>). Hence, sub-library screens using about 6000&#x02013;9000 sgRNAs are technically feasible in CMT-derived organoids.</p></sec><sec id="sec3dot2-vetsci-12-00183"><title>3.2. Pooled CRISPR/Cas9 Screening Targeting the Canine Epigenome in PDOs to Better Understand CMT Biology and Tumorigenesis</title><p>The first screen aimed to understand which epigenetic alterations may be crucial for the growth of CMTs but dispensable for normal mammary epithelial cells derived from the same individual patient. When comparing sgRNA enrichment between D40 and pDNA, some sgRNAs were clearly enriched for both organoid lines (log fold change = LFC &#x0003e; 1 and <italic toggle="yes">p</italic>-value &#x0003c; 0.05), matching genes known to bring a survival benefit for the cells when the gene is knocked-out, like SETD2 (coding for a histone methyltransferase containing a transcriptional activation domain) and CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) (labeled in red in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>c and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2b</xref>). Regarding &#x0201c;drop-off&#x0201d;, sgRNA targeting genes involved in essential processes, such as SRSF1 (splicing factor) or POLR2 (RNA polymerase II), were depleted in both organoid lines (core-specific essential genes, labeled in green in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>c, left part of <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>e and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2b</xref>). Based on previous essentialome screens using human cell lines, these canine homologs were expected to come up as significant hits [<xref rid="B40-vetsci-12-00183" ref-type="bibr">40</xref>], further supporting the good quality of the screen.</p><p>In this &#x0201c;epigenome&#x0201d; screen, we identified 133 genes to be significantly depleted (LFC &#x0003c; &#x02212;1 and <italic toggle="yes">p</italic>-value &#x0003c; 0.05) in the carcinoma organoid line (ORG-63-C) and 61 genes to be significantly depleted in the non-neoplastic mammary organoid line (ORG-63-N) (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S3</xref>). We were particularly interested in the genes essential for ORG-63-C but not essential for ORG-63-N (LFC &#x0003e; &#x02212;1 or <italic toggle="yes">p</italic>-value &#x0003e; 0.05) (context-specific essential genes, in bold in <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S3</xref>). Targeting those genes may lead to carcinoma cell death while preventing damage to the non-neoplastic cells. This comparison yielded 45 candidates listed in <xref rid="vetsci-12-00183-t001" ref-type="table">Table 1</xref> (see also the genes labeled in orange in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>c, right part of <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>e, and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2b,d</xref>).
<fig position="anchor" id="vetsci-12-00183-f001"><label>Figure 1</label><caption><p>Two independent pooled CRISPR/Cas9 screening approaches in paired CMT organoids identified therapeutic vulnerabilities of canine mammary carcinoma.</p></caption><graphic xlink:href="vetsci-12-00183-g001" position="float"/></fig>
<list list-type="alpha-lower"><list-item><p>Outline of the screens performed with a custom canine CRISPR/Cas9 library</p></list-item><list-item><p>Volcano plot representing depleted (LFC &#x0003c; 0) and enriched (LFC &#x0003e; 0) genes for ORG-63-C forty days (D40) after D0 for the druggable screen. LFC and <italic toggle="yes">p</italic>-values were calculated from two technical replicates with MAGeCK analysis. Each dot represents one gene for which at least four sgRNAs (out of six) were enrolled in the analysis. Selected hits are color-coded.</p></list-item><list-item><p>Volcano plot representing depleted (LFC &#x0003c; 0) and enriched (LFC &#x0003e; 0) genes for ORG-63-C forty days (D40) after D0 for the epigenome screen. LFC and <italic toggle="yes">p</italic>-values were calculated from two technical replicates with MAGeCK analysis. Each dot represents one gene for which at least four sgRNAs (out of six) were enrolled in the analysis. Selected hits are color-coded.</p></list-item><list-item><p>Scatter plot of the log fold change (LFC) of ORG-63-C and ORG-63-N for the druggable screen. Each dot represents one gene for which at least four sgRNAs (out of six) were enrolled in the analysis, and the <italic toggle="yes">p</italic>-value &#x0003c; 0.05 for at least one of the two ORG lines. Selected hits are color-coded.</p></list-item><list-item><p>Scatter plot of the log fold change (LFC) of ORG-63-C and ORG-63-N for the epigenome screen. Each dot represents one gene for which at least four sgRNAs (out of six) were enrolled in the analysis, and the <italic toggle="yes">p</italic>-value &#x0003c; 0.05 for at least one of the two ORG lines. Selected hits are color-coded.</p></list-item></list>
<table-wrap position="anchor" id="vetsci-12-00183-t001"><object-id pub-id-type="pii">vetsci-12-00183-t001_Table 1</object-id><label>Table 1</label><caption><p>Hits essential in ORG-63-C but dispensable in ORG-63-N (epigenome screen).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_C</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_C</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPEN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Msx2-interacting protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9141</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.531</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02454</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.126</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VPS72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vacuolar protein sorting-associated protein 72 homolog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8979</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4675</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01602</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.577</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLOD2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8599</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6872</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01308</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.333</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCOR1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclear receptor co-repressor 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7682</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25754</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.021244</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.889</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SRSF2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serine/arginine-rich splicing factor 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6809</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46804</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015419</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.955</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HDAC1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histone deacetylase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.6639</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045327</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.647</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACTL6A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Actin-like protein 6A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60347</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48882</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009406</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.670</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBL1X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F-box-like/WD repeat-containing protein TBL1X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60168</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4438</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.046566</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.318</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAZ1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bromodomain adjacent to zinc finger domain protein 1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.59139</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.2259</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014092</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.371</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOC2L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleolar complex protein 2 homolog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58843</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4693</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.018451</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.221</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TAF8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription initiation factor TFIID subunit 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58046</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3521</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.018177</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.594</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TFDP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription factor Dp-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46931</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3727</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033807</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.012</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBX5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chromobox protein homolog 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45174</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40584</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.039584</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.473</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SMARCA5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SWI/SNF-related matrix-associated actin-dependent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44409</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87841</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013878</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.98</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SRRM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serine/arginine repetitive matrix protein 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43516</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4318</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.859</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COPS5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information COP9 signalosome complex subunit 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43285</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75487</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.111</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAP1L1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleosome assembly protein 1-like 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40623</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024866</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.719</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HASPIN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serine/threonine-protein kinase haspin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40398</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.5946</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007778</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.185</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCC1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulator of chromosome condensation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39469</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23547</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01764</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.503</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OIP5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Mis18-beta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38418</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7262</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.018399</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.218</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SRSF5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Splicing factor, arginine/serine-rich 4/5/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34631</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.8543</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04839</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.951</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIS18BP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mis18-binding protein 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34095</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.0051</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBPMS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA binding protein, mRNA processing factor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9347</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.047674</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.959</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SETD1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histone-lysine N-methyltransferase SETD1A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32603</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.6491</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.020014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.490</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDK2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin-dependent kinase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7495</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.354</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USP7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitin carboxyl-terminal hydrolase 7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31791</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.0529</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.027406</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.860</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUZ12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUZ12 Polycomb repressive complex 2 subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31684</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4537</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019363</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.057</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DHX38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31248</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.6269</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025534</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.534</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KDM8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JmjC-domain-containing protein 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30885</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.8832</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007473</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.061</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OTUB1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitin thioesterase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9042</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017099</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.689</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTF3C4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General transcription factor 3C polypeptide 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29667</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.1029</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.048652</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.046</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CENPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histone H3-like centromeric protein A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2798</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.8915</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008441</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.949</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZZZ3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZZ-type zinc finger-containing protein 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26212</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.8331</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017243</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.213</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHEK1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serine/threonine-protein kinase Chk1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25733</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0502</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02631</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.563</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DDX17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Probable ATP-dependent RNA helicase DDX17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24814</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56402</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031922</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNAPC4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">snRNA-activating protein complex subunit 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24499</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9796</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.021048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.847</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MED30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mediator Complex Subunit 30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17747</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.6267</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.51 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.719</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proliferating cell nuclear antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14632</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.6846</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.012683</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.062</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein ecdysoneless homolog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12707</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.2861</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.026677</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.026</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSF1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remodeling and spacing factor 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11897</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7464</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.032301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.881</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UBE2A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitin-conjugating enzyme E2 A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11589</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9619</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010972</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.337</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTF2B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcription initiation factor IIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1149</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7796</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023854</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.791</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SMC2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Structural maintenance of chromosomes protein 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10679</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3809</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006639</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.191</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RUVBL1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RuvB-like 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.096328</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44603</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0039294</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.093</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AURKB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aurora kinase B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.068751</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9429</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0055614</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.071</td></tr></tbody></table></table-wrap></p><p>A string analysis network [<xref rid="B41-vetsci-12-00183" ref-type="bibr">41</xref>] of those candidates revealed that they are involved in many different biological processes, such as chromatin or chromosome organization, histone modification, transcription regulation, or organelle organization (118 Gene Ontology (GO) Processes involved in total, see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S4</xref>). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways involved were cell cycle and viral carcinogenesis [<xref rid="B42-vetsci-12-00183" ref-type="bibr">42</xref>].</p><p>Overall, this epigenome screen identified numerous candidates involved in critical biological processes. Validating those hits may reveal interesting pathways worth exploring to understand CMT carcinogenesis better.</p></sec><sec id="sec3dot3-vetsci-12-00183"><title>3.3. Pooled CRISPR/Cas9 Screening in PDOs to Identify Potential Drug Targets for CMTs</title><p>As many of those hits identified in the epigenome screen do not have known inhibitors, and our main aim was to find concrete new treatment options for CMTs, we moved forward to our second screening approach. This second screen aimed to identify actual therapeutic vulnerabilities of CMTs for which inhibitors exist to develop new therapeutic options for CMTs. For this purpose, we investigated which &#x0201c;druggable&#x0201d; genes are essential in PDOs derived from mammary carcinoma tissue but not in PDOs derived from normal mammary tissue.</p><p>When comparing sgRNA enrichment between D40 and pDNA, some sgRNAs were clearly enriched for both organoid lines (LFC &#x0003e; 1 and <italic toggle="yes">p</italic>-value &#x0003c; 0.05), matching genes known to bring a survival benefit for the cells when the gene is knocked-out, like TP53, NF2 (Neurofibromin-2), and CDKN2A (labeled in red in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>b and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2a</xref>). Moreover, genes involved in essential processes, such as the proto-oncogene MYC or DNA Topoisomerase II Alpha TOP2A, were depleted in both organoid lines (core-specific essential genes, labeled in green in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>b, left part of <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>d and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2a</xref>). Those genes, for which the behavior was expected based on published human essentialome screens [<xref rid="B40-vetsci-12-00183" ref-type="bibr">40</xref>], represented an additional quality control of the screen.</p><p>For the &#x0201c;druggable&#x0201d; screen, we identified 87 genes significantly depleted (LFC &#x0003c; &#x02212;1 and <italic toggle="yes">p</italic>-value &#x0003c; 0.05) in the carcinoma organoid line (ORG-63-C) and 65 genes significantly depleted in the non-neoplastic mammary organoid line (ORG-63-N) (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S5</xref>). We were particularly interested in the genes essential for ORG-63-C but not essential for ORG-63-N (LFC &#x0003e; &#x02212;1 or <italic toggle="yes">p</italic>-value &#x0003e; 0.05) (context-specific essential genes, in bold in <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S5</xref>). Indeed, targeting those candidates may result in neoplastic cell death without damaging the healthy cells. The 17 candidates from this analysis are listed in <xref rid="vetsci-12-00183-t002" ref-type="table">Table 2</xref> (see the genes labeled in orange in <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>b, right part of <xref rid="vetsci-12-00183-f001" ref-type="fig">Figure 1</xref>d, and <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S2a,c</xref>).</p><p>A string analysis network [<xref rid="B41-vetsci-12-00183" ref-type="bibr">41</xref>] of those candidates revealed that they are involved in many different biological processes, such as mitotic cell cycle and regulation, DNA repair, and DNA replication (40 Gene Ontology Processes involved in total, see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S6</xref>). The KEGG pathways involved were the Fanconi anemia pathway, cell cycle, PI3K-Akt signaling pathway, measles, p53 signaling pathway, human T-cell leukemia virus 1 infection, prostate cancer, small cell lung cancer, pathways in cancer, base excision repair, DNA replication, NOD-like receptor signaling pathway, viral carcinogenesis, nucleotide excision repair, Epstein&#x02013;Barr virus infection, and shigellosis [<xref rid="B42-vetsci-12-00183" ref-type="bibr">42</xref>].</p><p>In summary, this &#x0201c;druggable&#x0201d; screen identified several candidates involved in different key biological processes, which may be attractive targets for CMT treatment. Both screens highlighted the increased essentiality of some genes in the neoplastic organoid line compared to the non-neoplastic organoid line. Notably, CDK2 appeared as a candidate overlapping between the two screens, which strengthened its biological relevance and made it a particularly compelling target for further investigation. We then wondered if this increased essentiality of some genes in the neoplastic organoid line compared to the non-neoplastic organoid line might also be represented in a difference in gene expression levels between primary tumor tissues and non-neoplastic mammary tissues.</p></sec><sec id="sec3dot4-vetsci-12-00183"><title>3.4. Candidates from the CRISPR/Cas9 Screens Are Expressed in Primary Tumor Tissues and PDOs but Very Rarely Differentially Expressed Compared to the Non-Neoplastic Mammary Tissues</title><p>To obtain more insights into CMT biology and investigate how our different hits were expressed in normal and carcinoma mammary tissues, we first performed RNA sequencing of 34 carcinomas and 17 non-neoplastic mammary tissues (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S7</xref>). Among these samples, we had 15 pairs (matched carcinoma/healthy mammary tissue) from 10 different patients (some dogs presented different tumors), including the pair the organoids for the screens were derived from (D63_3_CMT/D63_nor). The quality controls of the samples were satisfactory. Then, gene expression level determination (assessed by calculating the FPKM [expected number of fragments per kilobase of transcript sequence per millions base pairs sequenced], which takes the effects of both sequencing depth and gene length into consideration) and differential gene expression analysis could be performed. After assessing the gene expression level, we hierarchically clustered our samples depending on the gene expression level (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S3a</xref>). Together with this clustering, principal component analysis of all sequenced samples generated using FPKM (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S3b</xref>) revealed that a pool of non-neoplastic mammary tissues cluster very distinctly from the rest of the samples (D18_nor, D15_nor, D17_nor, D48_nor, D20_nor, D31_nor). However, the rest of the non-neoplastic mammary tissues cluster together with the carcinoma samples (D57_nor, D32_nor, D37_nor, D49_nor, D6_nor, D63_nor, D44_nor, D62_nor, D46_nor, D36_nor, D60_nor). Most likely, this is due to the gene expression derived from the non-neoplastic stromal cells that are also collected with the carcinoma samples. Indeed, differential gene expression between those two groups of normal mammary tissues showed that genes involved in immune response, leucocyte activation, and inflammatory response are upregulated in the normal tissues that cluster close to the carcinomas. As carcinomas are surrounded by inflammatory cells (inflammatory tumor microenvironment), this might explain why those two populations cluster together [<xref rid="B43-vetsci-12-00183" ref-type="bibr">43</xref>,<xref rid="B44-vetsci-12-00183" ref-type="bibr">44</xref>]. By contrast, the other pool of normal mammary tissues that clusters very distinctly from the rest of the samples is probably composed of non-neoplastic epithelial cells without an inflammatory component. Another explanation might be that some mammary tissues defined macroscopically as &#x0201c;normal&#x0201d; already had genetic aberrations similar to those in the CMTs. Indeed, carcinogenesis in CMTs is thought to follow a stepwise evolution from hyperplastic lesions to adenomas to carcinomas [<xref rid="B6-vetsci-12-00183" ref-type="bibr">6</xref>]. Therefore, sequencing adenoma samples and comparing their gene expression levels with this pool of &#x0201c;normal&#x0201d; samples that cluster close to the carcinomas might shed light on another possible reason for this clustering difference.</p><p>After analyzing the differential gene expression between all CMT samples compared with all normal mammary tissue samples, we found that 2831 genes are significantly (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC| &#x0003e; 1.0) upregulated (labeled in red in <xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>a) and 3472 are significantly downregulated (labeled in green in <xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>a). Among the hits that are upregulated, many genes involved in metabolic pathways can be found (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S3c</xref>), as well as genes coding for collagen or adhesion proteins, such as cadherins, claudins, or hepatic and glial cell adhesion molecules. Additionally, keratins and keratin-associated proteins are strongly downregulated in tumor tissues (labeled in blue in <xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>a). We then investigated whether the candidate genes from the CRISPR screens that may be essential for tumor growth, but not for the growth of normal mammary epithelial cells, were expressed at higher levels in CMT tissues compared to normal tissues. <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S8</xref> details the LFC and <italic toggle="yes">p</italic>-value for the candidates of the CRISPR screens in this RNA sequencing analysis of all CMTs compared to all normal tissues. Most of the candidates functionally essential for ORG-63-C, but not for ORG-63-N, are found to be expressed in the CMTs, showing they are not just induced by the in vitro culture conditions. However, they do not appear differentially expressed (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC| &#x0003e; 1.0) in the tumor tissues compared to normal tissues (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S8</xref>). In fact, only two of our candidates from the epigenome screen (PLOD2 and CENPA) are upregulated when performing a differential gene expression analysis between the tissue ORG-63-C is derived from (D63_3_CMT) compared to the non-neoplastic tissue ORG-63-N is derived from (D63_nor) (labeled in orange in <xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>b). When focusing on CDK2, the common candidate from both screens, we found that CDK2 was expressed in tumor tissues and normal mammary tissue samples. Moreover, when comparing all tumor tissues to all healthy mammary tissue samples, CDK2 was slightly downregulated (with an LFC of &#x02212;0.63 and a <italic toggle="yes">p</italic>-value of 0.009, see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S8</xref>). However, this difference was not significant when focusing on the single pair D63_3_CMT/D63_nor.</p><p>We then set out to investigate the gene expression of our candidates in the organoid lines themselves. In these, stromal cells have been depleted due to the culture conditions, and one can compare the expression profiles of the neoplastic versus the non-neoplastic epithelium. For this purpose, we performed RNA sequencing of three matched pairs of organoids, including ORG-63-N and ORG-63-C. The other two were ORG-60-N/ORG-60-C (from dog D60) and ORG-17-N/ORG-17-C (from dog D17). The quality controls of the samples were satisfactory, and gene expression level and differential gene expression analysis could be performed. In addition, the principal component analysis generated using FPKM of all sequenced organoid samples (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S4a</xref>) revealed that dogs clustered together rather than according to their epithelial origins (carcinoma or non-neoplastic). This shows that the individual gene expression fingerprints of the epithelial cells are predominant over the gene expression of the tumor organoids versus the normal organoids.</p><p>Additionally, we compared the gene expression levels of primary tissues and organoids. Pearson&#x02019;s correlation heat map (generated using normalized reads per million mapped reads) shows that the organoid samples cluster separately from all primary tissues (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Figure S4b</xref>). Hence, although tumor-derived organoids keep features of the original tumor, as we have previously shown [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>], the culture conditions still induce a gene expression signature that differs considerably from the original tissues. This raises the question of whether the gene expression profiles of normal and neoplastic organoid samples from the same patient are similar due to the proliferation-inducing cell culture conditions that may mask the differences between neoplastic and non-neoplastic cells. To answer this question, we analyzed the differential gene expression between organoids derived from CMTs and those derived from normal mammary tissues. As a result, we found that 109 genes are significantly (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC| &#x0003e; 1.0) upregulated (labeled in red in <xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>c) and 129 are significantly downregulated (labeled in green in <xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>c). After GO enrichment analysis, we observed that, on the one hand, many genes significantly upregulated in organoids derived from CMTs are involved in growth factor binding, signaling receptor binding, and peptidase regulator activity (<xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>d). On the other hand, we found that genes significantly downregulated in organoids derived from CMTs are mainly involved in transmembrane receptor protein tyrosine kinase activity and multicellular organism development (<xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>d). Then, we investigated whether the candidates from the CRISPR screens were differentially expressed in organoids derived from CMTs compared with organoid samples derived from normal mammary tissues. Most of the candidates were expressed in the organoid lines but, in all cases, organoid line-specific essentiality (genes that are functionally essential for ORG-63-C but not for ORG-63-N) did not reflect differential expression (see <xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S9</xref>).</p><p>In summary, despite substantial differences between organoids and primary tissues regarding gene expression, our data show that the candidates from the CRISPR/Cas9 screens are also expressed in the primary tumors and therefore are not just induced by the in vitro culture conditions. Moreover, our results suggest that increased essentiality is not represented by increased gene expression levels in tumor tissues or tumor-derived organoids. In addition, when comparing the results of our two independent screens, we identified CDK2 as a common hit for both screens and set out to validate this candidate (<xref rid="vetsci-12-00183-f002" ref-type="fig">Figure 2</xref>).
<fig position="anchor" id="vetsci-12-00183-f002"><label>Figure 2</label><caption><p>Candidates from the CRISPR/Cas9 screens are expressed in primary tumor tissues and PDOs but very rarely differentially expressed compared to the non-neoplastic mammary tissues.</p></caption><graphic xlink:href="vetsci-12-00183-g002" position="float"/></fig>
<list list-type="alpha-lower"><list-item><p>Volcano plot representing downregulated (log fold change = LFC &#x0003c; 0) and upregulated (LFC 0) genes between all CMT samples compared with all normal mammary tissue samples. Significantly (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC|&#x0003e; = 1.0) downregulated (green) and upregulated (red) are color coded. Keratins and keratin-associated proteins are labeled in blue.</p></list-item><list-item><p>Volcano plot representing significantly downregulated and upregulated (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC| &#x0003e; 1.0) genes between D63_3_CMT and D63_nor. Candidates from the CRISPR/Cas9 screens that are differentially expressed between D63_3_CMT and D63_nor are labeled in orange.</p></list-item><list-item><p>Volcano plot representing downregulated (LFC &#x0003c; 0) and upregulated (LFC &#x0003e; 0) genes between three organoid lines derived from carcinomas compared with their matched organoids derived from normal mammary tissues. Significantly (<italic toggle="yes">p</italic>-value &#x0003c; 0.05 and |LFC| &#x0003e; 1.0) downregulated (green) and upregulated (red) are color coded.</p></list-item><list-item><p>Bar plot showing Gene Ontology (biological processes) analysis results of all differentially expressed genes between three organoid lines derived from carcinomas compared with their matched organoids derived from normal mammary tissues. The color of each bar represents the <italic toggle="yes">p</italic>-value of each term involved in the analysis, and the bar size represents the gene counts for this term.</p></list-item></list></p></sec><sec id="sec3dot5-vetsci-12-00183"><title>3.5. CDK2 May Be a Druggable Vulnerability for CMTs</title><p>To overcome the limitation of gene essentiality, where a direct genetic knock-out unequivocally leads to cell death, we proceeded to validate our candidate with known inhibitors. Unfortunately, a sole inhibitor for CDK2 does not exist [<xref rid="B45-vetsci-12-00183" ref-type="bibr">45</xref>], as many CDK2 inhibitors also have an affinity for CDK1, which is highly essential for normal tissues [<xref rid="B46-vetsci-12-00183" ref-type="bibr">46</xref>]. PF3600 is a recently developed selective CDK2/4/6 inhibitor [<xref rid="B47-vetsci-12-00183" ref-type="bibr">47</xref>]. As <italic toggle="yes">CDK4</italic> and <italic toggle="yes">CDK6</italic> were also targeted by our CP1736 &#x0201c;druggable&#x0201d; library, we first checked whether they appeared to be essential in ORG-63-N. This was not the case with an LFC &#x0003e; &#x02212;1 or <italic toggle="yes">p</italic>-value &#x0003e; 0.05 for ORG-63-N (<xref rid="vetsci-12-00183-t003" ref-type="table">Table 3</xref>), and we proceeded to test this inhibitor on our two organoid lines.</p><p>A drug viability assay showed that ORG-63-C was more sensitive to PF3600 than ORG-63-N, validating <italic toggle="yes">CDK2</italic> as a vulnerability of ORG-63-C that can be targeted (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>a). In addition, the IC50 found (0.53 &#x000b5;M and 0.16 &#x000b5;M) were compatible with drug concentrations tolerated in mice [<xref rid="B48-vetsci-12-00183" ref-type="bibr">48</xref>]. Although ORG-63-C exhibited approximately a 3-fold increased sensitivity, the difference in IC50 is modest, suggesting that more specific inhibitors may provide clearer specificities in the future.</p><p>In addition, we tested three other hits from the druggable screen&#x02014;TOP2B, TTK, and HSP90AA1&#x02014;using the commercially available inhibitors doxorubicin [<xref rid="B49-vetsci-12-00183" ref-type="bibr">49</xref>], reversine [<xref rid="B50-vetsci-12-00183" ref-type="bibr">50</xref>], and luminespib [<xref rid="B51-vetsci-12-00183" ref-type="bibr">51</xref>], respectively. ORG-63-C appeared more sensitive to doxorubicin than ORG-63-N (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>b), while no difference was observed for reversine (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>c) and luminespib (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>d).</p><p>While doxorubicin remains toxic for ORG-63-N (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>a) as it also targets the shared essential topoisomerase TOP2A, its lethal effect appears stronger for ORG-63-C, for which TOP2B is essential in addition. This could indicate the presence of compensatory mechanisms in ORG-63-N, which may limit the drug&#x02019;s efficacy in this line.</p><p>Conversely, ORG-63-C did not appear more sensitive to reversine (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>c), chosen initially as a TTK inhibitor. However, reversine is also an inhibitor of Aurora A and B kinases. According to our druggable screen results (<xref rid="app1-vetsci-12-00183" ref-type="app">Supplementary Table S5</xref>), AURKB and AURKA are essential (LFC &#x0003c; &#x02212;1 and <italic toggle="yes">p</italic>-value &#x0003c; 0.05) for both organoid lines, which can explain the similar response to reversine when treating ORG-63-N and ORG-63-C. We also did not see any difference with luminespib (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>d), an inhibitor of subunits &#x003b1; and &#x003b2; of HSP90 [<xref rid="B52-vetsci-12-00183" ref-type="bibr">52</xref>]. Known off-target effects of luminespib on different kinases, which might be essential for both organoid lines, could explain this result [<xref rid="B53-vetsci-12-00183" ref-type="bibr">53</xref>].</p><p>Overall, after identifying CDK2 as a common hit in both unbiased screening approaches, our drug assay using PF3600 validated CDK2 function as a potentially interesting essentiality for CMTs to be targeted with a selective inhibitor (<xref rid="vetsci-12-00183-f003" ref-type="fig">Figure 3</xref>).
<fig position="anchor" id="vetsci-12-00183-f003"><label>Figure 3</label><caption><p>ORG-63-C is more sensitive to PF3600 and doxorubicin than ORG-63-N.</p></caption><graphic xlink:href="vetsci-12-00183-g003" position="float"/></fig>
<list list-type="alpha-lower"><list-item><p>Dose-response curves illustrating the effect of PF3600 on cell viability in organoid lines ORG-63-C and ORG-63-N. Error bars represent the standard deviation (SD) of three independent experiments. Statistical analysis of the log-transformed IC50 values was performed using an unpaired <italic toggle="yes">t</italic>-test, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001. IC50s are indicated in the figure legend.</p></list-item><list-item><p>Dose-response curves illustrating the effect of doxorubicin on cell viability in organoid lines ORG-63-C and ORG-63-N. Error bars represent the standard deviation (SD) of three independent experiments. Statistical analysis of the log-transformed IC50 values was performed using an unpaired <italic toggle="yes">t</italic>-test, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001. IC50s are indicated in the figure legend.</p></list-item><list-item><p>Dose-response curves depicting the effect of reversine on cell viability in organoid lines ORG-63-C and ORG-63-N. Error bars represent the standard deviation (SD) of three independent experiments. Statistical analysis of the log-transformed IC50 values was performed using an unpaired <italic toggle="yes">t</italic>-test, ns = non-significant. IC50s are indicated in the figure legend.</p></list-item><list-item><p>Dose-response curves depicting the effect of luminespib on cell viability in organoid lines ORG-63-C and ORG-63-N. Error bars represent the standard deviation (SD) of three independent experiments. Statistical analysis of the log-transformed IC50 values was performed using an unpaired <italic toggle="yes">t</italic>-test, ns = non-statistical. IC50s are indicated in the figure legend.</p></list-item></list></p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00183"><title>4. Discussion</title><p>In this study, conducted with CRISPR/Cas9 screenings using two custom-designed canine sub-libraries on paired canine mammary PDOs derived from both the non-neoplastic and cancerous mammary tissues of a single donor. While CRISPR/Cas9-based approaches have been used in carcinogenesis studies with colon organoids [<xref rid="B25-vetsci-12-00183" ref-type="bibr">25</xref>,<xref rid="B54-vetsci-12-00183" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-12-00183" ref-type="bibr">55</xref>], to the best of our knowledge, the use of paired non-neoplastic and cancerous mammary PDOs was first demonstrated in our previous study, due to the challenges in obtaining normal human mammary tissue from HBC patients [<xref rid="B11-vetsci-12-00183" ref-type="bibr">11</xref>] Our approach helps mitigate the bias associated with inter-individual genetic variability.</p><p>Following this unbiased approach, CDK2 was identified as a common candidate in both screens, essential for the malignant PDOs but dispensable for the normal PDOs. This context-specific essential gene may be a useful therapeutic target with high effectiveness and minimal side effects (concept of synthetic lethality [<xref rid="B18-vetsci-12-00183" ref-type="bibr">18</xref>].</p><p>CDKs 1, 2, 4, and 6 play an essential role in cell cycle regulation [<xref rid="B56-vetsci-12-00183" ref-type="bibr">56</xref>] and control progression through each of the four phases of the cell cycle (G1, S, G2, and M). While targeting the cell cycle as an opportunity for cancer treatment is not novel in human oncology, it remains underexplored in a veterinary setting [<xref rid="B57-vetsci-12-00183" ref-type="bibr">57</xref>]. For example, selective pharmacological inhibition of CDK4/6 showed promising results in HBC, with the CDK4/6 dual inhibitor palbociclib being approved in combination with the aromatase inhibitor letrozole in 2015 for treating ER+ HBC patients [<xref rid="B58-vetsci-12-00183" ref-type="bibr">58</xref>]. However, patients often develop resistance to selective CDK4/6 inhibitors with different mechanisms involved, among which is the activation of MYC and CDK2. Combined inhibition of CDK2/4/6 shows promising in vitro and in vivo results [<xref rid="B48-vetsci-12-00183" ref-type="bibr">48</xref>], and the CDK2/4/6 inhibitor PF3600 is currently being tested in a phase I clinical trial for different types of HBC [<xref rid="B59-vetsci-12-00183" ref-type="bibr">59</xref>]. These insights suggest that further exploration of CDK2 inhibition may be promising in CMT therapy.</p><p>In parallel with CDK inhibition, CRISPR/Cas9 holds potential for directly targeting specific genes, offering a strategy for overcoming the resistance. However, the use of CRISPR/Cas9 for in vivo treatments is still in its infancy and remains limited due to concerns over safety, off target effects, and delivery efficacy [<xref rid="B60-vetsci-12-00183" ref-type="bibr">60</xref>]. Nonetheless, its application in preclinical models, such as PDOs, offers valuable insights on how gene editing tools could be leveraged for potential therapeutic interventions in the future.</p><p>Conventional chemotherapy does not appear to provide a clear advantage for dogs suffering from CMTs [<xref rid="B5-vetsci-12-00183" ref-type="bibr">5</xref>], and owners are highly motivated to find novel options for the treatment of cancer in their pets. Therefore, preclinical studies using CMT organoids could help predict the treatment efficacy before clinical trials. For example, known inhibitors, such as PF3600, can be tested first in CMT organoids to predict therapy efficacy, followed by testing in CMT-bearing dogs to assess the safety and efficacy, leading to translatable results [<xref rid="B61-vetsci-12-00183" ref-type="bibr">61</xref>]. Furthermore, as dogs share the same environment as their owners and are exposed to the same carcinogens as humans, the tumors they develop might be influenced by similar epigenetic regulation processes.</p><p>Studies investigating the epigenetic landscape in canine cancer are scarce, very few focus on CMTs and have enough samples to draw solid conclusions (for a review, see [<xref rid="B62-vetsci-12-00183" ref-type="bibr">62</xref>]). For example, a study found only one CMT sample (out of fifteen) displaying BRCA1 hypermethylation, which might explain the downregulation of BRCA1 in a few cases [<xref rid="B63-vetsci-12-00183" ref-type="bibr">63</xref>,<xref rid="B64-vetsci-12-00183" ref-type="bibr">64</xref>]. No variation in methylation patterns was found between ER&#x003b1;-positive CMTs and ER&#x003b1;-negative CMTs, indicating that deregulation of ER&#x003b1; in CMTs, contrary to HBC, is not attributed to <italic toggle="yes">ER&#x003b1;</italic> promoter methylation [<xref rid="B65-vetsci-12-00183" ref-type="bibr">65</xref>]. Genome-wide methylation studies have been performed, but only for two dogs [<xref rid="B66-vetsci-12-00183" ref-type="bibr">66</xref>]. EZH2 (enhancer of zeste homolog 2), a crucial epigenetic regulator overexpressed in HBC, was overexpressed in CMTs, and its expression level (determined with immunohistochemistry) was associated with the degree of malignancy of the CMTs [<xref rid="B67-vetsci-12-00183" ref-type="bibr">67</xref>].</p><p>It has also been suggested that complex carcinomas originate from epigenetic rather than genomic alterations. Indeed, a pioneering study showed that complex carcinomas (four cases), compared to simple carcinomas (seven cases), displayed several epigenetic dysregulations, such as downregulation of chromatin-modification genes or enriched activating histone modification H4-acetylation, while showing a reduction in the repressive histone modification H3K9me3 [<xref rid="B68-vetsci-12-00183" ref-type="bibr">68</xref>]. The first evidence of microRNA (miRNA) dysregulation in canine tumors was described for CMT samples, where both <italic toggle="yes">miR-29</italic> and <italic toggle="yes">miR-29b</italic> were upregulated in CMTs [<xref rid="B69-vetsci-12-00183" ref-type="bibr">69</xref>]. Ten miRNA (<italic toggle="yes">cfa-let-7c</italic>, <italic toggle="yes">cfa-miR-10b</italic>, <italic toggle="yes">cfa-miR-26a</italic>, <italic toggle="yes">cfa-miR-26b</italic>, <italic toggle="yes">cfa-miR-29c</italic>, <italic toggle="yes">cfa-miR-30a</italic>, <italic toggle="yes">cfamiR-30b</italic>, <italic toggle="yes">cfa-miR-30c</italic>, <italic toggle="yes">cfa-miR-148a</italic>, and <italic toggle="yes">cfa-miR-299</italic>) showed significant different expression in metastatic and non-metastatic CMTs [<xref rid="B70-vetsci-12-00183" ref-type="bibr">70</xref>]. CMT cells also appear to shed exosomes containing differentially expressed miRNA compared to normal cells [<xref rid="B71-vetsci-12-00183" ref-type="bibr">71</xref>]. These few descriptive studies already show interesting aspects of epigenetic regulation in CMTs and highlight the urgent need for further studies investigating the epigenetic players in CMTs. Our epigenome screen yielded exciting new candidates, and validation of those hits will bring our understanding of CMT tumorigenesis forward.</p><p>In the future, however, for an optimal validation of our different candidates, we need to overcome the limitation of gene essentiality, where a direct genetic knock-out unequivocally leads to cell death. To avoid this problem, in this study, we worked with known inhibitors when they were available. However, they are not always specific and target either other genes (off-target effects) or both subunits of the same protein. In this context, a gene-editing approach to confirm the phenotype induced by the studied mutation is ideal. For this purpose, knockdown systems are helpful for studying essential genes. RNA interference with short-hairpin RNAs (shRNAs) or short-interfering RNAs (siRNAs) can be used in organoids, even if the process is more challenging than in 2D cell cultures [<xref rid="B72-vetsci-12-00183" ref-type="bibr">72</xref>,<xref rid="B73-vetsci-12-00183" ref-type="bibr">73</xref>]. However, they show lower efficacy and are also prone to off-target effects. Different inducible systems to trigger gene knockouts or knockdowns have been explored, some of which remain to be adapted to organoid cultures [<xref rid="B74-vetsci-12-00183" ref-type="bibr">74</xref>]. For example, an inducible gene knockdown method with a doxycycline-inducible system was established in a human lung PDO [<xref rid="B75-vetsci-12-00183" ref-type="bibr">75</xref>]. Another powerful method that could be applied to organoid cultures is the CRISPR-FLIP, which is based on the homology-directed repair mediated insertion of a Cre/loxP invertible cassette into an intronic region of a target gene [<xref rid="B76-vetsci-12-00183" ref-type="bibr">76</xref>]. Then, the auxin-induced degron (AID) approach showed that AID tagging, in combination with CRISPR/Cas9 mediated gene targeting, results in the rapid degradation of proteins [<xref rid="B77-vetsci-12-00183" ref-type="bibr">77</xref>,<xref rid="B78-vetsci-12-00183" ref-type="bibr">78</xref>]. However, this technique remains to be established in organoid culture. Therefore, many different approaches can be tested for the functional analysis of essential genes in organoids.</p><p>Our RNA sequencing analysis revealed significant differences between organoids and primary tissues when focusing on gene expression. This poses a challenge in fully mimicking the primary tissue in vitro. A direct transcriptomic comparison to paired primary tissue has not yet been performed for HBC-derived organoids, with RNA sequencing data from organoids only being compared to published datasets [<xref rid="B79-vetsci-12-00183" ref-type="bibr">79</xref>]. Despite the advances in organoid technology, and their closer resemblance to primary tissues compared to 2D cell cultures, there are still some limitations when focusing on gene expression.</p><p>These differences can be explained through different aspects. First of all, the growth medium used for the organoid culture enhances the growth of epithelial cells, and the other non-epithelial components of the primary tumor are lost. Therefore, gene expression from stromal cells of the tumor microenvironment that do not grow in the traditional organoid cultures may contribute to the differences in gene expression between primary tumors and organoids and possibly lead to an unclear distinction between normal and neoplastic cells. In the future, spatial transcriptomics could be useful in resolving this issue [<xref rid="B80-vetsci-12-00183" ref-type="bibr">80</xref>]. Indeed, this next-generation molecular profiling technique allows the mapping of the whole transcriptome with morphological context on the slide in FFPE or fresh frozen tissues. Then, the primary samples&#x02019; heterogeneity might account for the transcriptomic differences between organoids and primary tissues. Indeed, different tissue pieces are used for RNA sequencing and organoid derivation.</p><p>In addition, it is sometimes impossible to macroscopically differentiate between non-neoplastic mammary tissues and pre-neoplastic or benign lesions when collecting tissues for the organoid biobank. As CMT tumorigenesis is thought to follow a stepwise evolution from adenomas to carcinomas [<xref rid="B6-vetsci-12-00183" ref-type="bibr">6</xref>], comparing the gene expression levels of adenomas with non-neoplastic mammary tissue samples might shed light on this process. Next, messenger RNA (mRNA) expression might vary depending on the tumor stage or the samples&#x02019; freezing conditions (some CMT samples were shipped overnight and kept at 4 &#x000b0;C during transport, leading to possible mRNA degradation).</p><p>Despite the differences in gene expression between organoids and primary tissues, the gene candidates from the CRISPR/Cas9 screens are also expressed in the primary tumors, suggesting that these differences are not solely due to the in vitro culture conditions. However, further validation would be necessary to confirm this to rule out potential artifacts from the culture systems. Additionally, our results suggest that increased essentiality is not represented by increased gene expression levels in tumor tissues or tumor-derived organoids. Indeed, standard gene expression profiling and other &#x0201c;omics&#x0201d; techniques do not usually pick up on subtle modifications. If some essential genes can be overexpressed, as is sometimes the case [<xref rid="B81-vetsci-12-00183" ref-type="bibr">81</xref>], it is not necessary because gene function does not automatically reflect itself on gene expression. If we had performed a genome-wide CRISPR/Cas9 screen, we would probably have found more essential genes that were also upregulated, but with such a small dataset of essential genes from our pooled libraries, it is unsurprising that very few of them are overexpressed. Similarly, Hu et al. [<xref rid="B82-vetsci-12-00183" ref-type="bibr">82</xref>], focusing on colon adenocarcinoma published datasets, found that, among 1166 essential genes identified with genome-scale CRISPR/Cas9 screening data, only 261 were significantly upregulated, based on RNA sequencing data from TCGA [<xref rid="B83-vetsci-12-00183" ref-type="bibr">83</xref>] and GTEx [<xref rid="B84-vetsci-12-00183" ref-type="bibr">84</xref>]. This suggests that combining RNA sequencing with functional screening approaches is critical for an understanding of tumor biology.</p><p>In summary, our data show the first analysis of two drop-out screens conducted with custom CRISPR/Cas9 libraries for canine PDOs developed from spontaneous CMTs and its matched healthy mammary tissue. Our approach has validated CDK2 as a therapeutic vulnerability for CMTs. Moreover, we showed the power of functionally testing gene essentiality in matched neoplastic versus non-neoplastic PDOs of an individual patient. This allows functional testing of hundreds of genes that can be targeted and provides valuable information about potential therapeutic approaches for a particular patient.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank John Doench and Adam Brown (Broad Institute of MIT and Harvard, Cambridge, MA, USA) for helping us designing the canine CRISPR sub-libraries.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00183"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020183/s1">https://www.mdpi.com/article/10.3390/vetsci12020183/s1</uri>, Figure S1: Quality control of the two different pooled CRISPR/Cas9 screens; Figure S2: Two independent pooled CRISPR/Cas9 screening approaches in paired CMT organoids to identify therapeutic vulnerabilities of canine mammary carcinoma; Figure S3: RNA sequencing of CMT and non-neoplastic mammary tissues; Figure S4: RNA sequencing of paired organoids derived from carcinoma and non-neoplastic mammary tissues and comparison to primary tissues; Table S1. All 1269 genes targeted by the custom canine CRISPR/Cas9 sub-library CP1737 and sgRNAs counts (plasmid DNA and day 0 and day 40 for both organoid lines); Table S2. All 834 genes targeted by the custom canine CRISPR/Cas9 sub-library CP1736 and sgRNAs counts (plasmid DNA and day 0 and day 40 for both organoid lines); Table S3. All hits for the epigenome screen; Table S4. Biological processes (Gene Ontology) of the essential genes for ORG-63-C dispensable for ORG-63-N (epigenome screen); Table S5. All hits for the &#x0201c;druggable&#x0201d; screen; Table S6. Biological processes (Gene Ontology) of the essential genes for ORG-63-C dispensable for ORG-63-N (druggable screen); Table S7. Details of the CMT and non-neoplastic tissues sent for RNA sequencing; Table S8. Differential genes analysis results for the candidates of the CRISPR screens in the RNA sequencing data from CMT (all tumors versus all normal samples); Table S9. Differential genes analysis results for the candidates of the CRISPR screens in the RNA sequencing data from organoids (all tumor organoids versus all normal organoids.</p><supplementary-material id="vetsci-12-00183-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00183-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.R. and M.I.; methodology, M.I., M.D., C.H., and E.M.; validation, M.I.; formal analysis, M.I., A.N., and L.O.; investigation, M.I.; resources, S.R.; data curation, M.I.; writing&#x02014;original draft preparation, M.I.; writing&#x02014;review and editing, M.I., C.H., and S.R.; visualization, M.I.; supervision, S.R.; project administration, S.R. and M.I.; funding acquisition, S.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All tissues used in this study were obtained from surplus tissue collected during mastectomy procedures in client-owned dogs, as part of their surgical treatment for mammary tumors. In accordance with the relevant Swiss law, an informed consent was obtained from the authorized welfare advocate of each participating dog to receive standard of care veterinary diagnostics and treatment and to be allowed to use excess tissues for research purposes.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Both custom CRISPR/Cas9 sub-libraries used in this publication are available in the <xref rid="app1-vetsci-12-00183" ref-type="app">supplementary material</xref>. Both raw and processed RNA sequencing data have been deposited in the European Nucleotide Archive (ENA) database under accession code PRJEB85459. Additional data can be made available upon reasonable request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CMT</td><td align="left" valign="top" rowspan="1" colspan="1">Canine Mammary Tumor</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRISPR</td><td align="left" valign="top" rowspan="1" colspan="1">Clustered Regularly Interspaced Short Palindromic Repeats</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D0</td><td align="left" valign="top" rowspan="1" colspan="1">Day 0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D40</td><td align="left" valign="top" rowspan="1" colspan="1">Day 40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HBC</td><td align="left" valign="top" rowspan="1" colspan="1">Human Breast Cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IC50</td><td align="left" valign="top" rowspan="1" colspan="1">Half Maximal Inhibitory Concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LFC</td><td align="left" valign="top" rowspan="1" colspan="1">Log Fold Change</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">mRNA</td><td align="left" valign="top" rowspan="1" colspan="1">Messenger RNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">pDNA</td><td align="left" valign="top" rowspan="1" colspan="1">Plasmid DNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDO</td><td align="left" valign="top" rowspan="1" colspan="1">Patient-Derived Organoid</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">sgRNA</td><td align="left" valign="top" rowspan="1" colspan="1">Single Guide RNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TCGA</td><td align="left" valign="top" rowspan="1" colspan="1">The Cancer Genome Atlas</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vetsci-12-00183"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rowell</surname><given-names>J.L.</given-names></name>
<name><surname>McCarthy</surname><given-names>D.O.</given-names></name>
<name><surname>Alvarez</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Dog Models of Naturally Occurring Cancer</article-title><source>Trends Mol. Med.</source><year>2011</year><volume>17</volume><fpage>380</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2011.02.004</pub-id><pub-id pub-id-type="pmid">21439907</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00183"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gr&#x000fc;ntzig</surname><given-names>K.</given-names></name>
<name><surname>Graf</surname><given-names>R.</given-names></name>
<name><surname>H&#x000e4;ssig</surname><given-names>M.</given-names></name>
<name><surname>Welle</surname><given-names>M.</given-names></name>
<name><surname>Meier</surname><given-names>D.</given-names></name>
<name><surname>Lott</surname><given-names>G.</given-names></name>
<name><surname>Erni</surname><given-names>D.</given-names></name>
<name><surname>Schenker</surname><given-names>N.S.</given-names></name>
<name><surname>Guscetti</surname><given-names>F.</given-names></name>
<name><surname>Boo</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>The Swiss Canine Cancer Registry: A Retrospective Study on the Occurrence of Tumours in Dogs in Switzerland from 1955 to 2008</article-title><source>J. Comp. Pathol.</source><year>2015</year><volume>152</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2015.02.005</pub-id><pub-id pub-id-type="pmid">25824119</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00183"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinello</surname><given-names>K.</given-names></name>
<name><surname>Pires</surname><given-names>I.</given-names></name>
<name><surname>Castro</surname><given-names>A.F.</given-names></name>
<name><surname>Carvalho</surname><given-names>P.T.</given-names></name>
<name><surname>Santos</surname><given-names>A.</given-names></name>
<name><surname>de Matos</surname><given-names>A.</given-names></name>
<name><surname>Queiroga</surname><given-names>F.</given-names></name>
<name><surname>Canadas-Sousa</surname><given-names>A.</given-names></name>
<name><surname>Dias-Pereira</surname><given-names>P.</given-names></name>
<name><surname>Catarino</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Cross Species Analysis and Comparison of Tumors in Dogs and Cats, by Age, Sex, Topography and Main Morphologies. Data from Vet-OncoNet</article-title><source>Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci9040167</pub-id><pub-id pub-id-type="pmid">35448665</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00183"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Rasotto</surname><given-names>R.</given-names></name>
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
</person-group><article-title>Classification and Grading of Canine Mammary Tumors</article-title><source>Vet. Pathol.</source><year>2011</year><volume>48</volume><fpage>117</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1177/0300985810393258</pub-id><pub-id pub-id-type="pmid">21266722</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00183"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Sorenmo</surname><given-names>K.U.</given-names></name>
<name><surname>Worley</surname><given-names>D.R.</given-names></name>
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
</person-group><article-title>Tumors of the Mammary Gland</article-title><source>Withrow and MacEwen&#x02019;s Small Animal Clinical Oncology</source><publisher-name>Saunders</publisher-name><publisher-loc>Birmingham, AL, USA</publisher-loc><year>2019</year><fpage>604</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/B978-0-323-59496-7.00028-1</pub-id></element-citation></ref><ref id="B6-vetsci-12-00183"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sorenmo</surname><given-names>K.U.</given-names></name>
<name><surname>Kristiansen</surname><given-names>V.M.</given-names></name>
<name><surname>Cofone</surname><given-names>M.A.</given-names></name>
<name><surname>Shofer</surname><given-names>F.S.</given-names></name>
<name><surname>Breen</surname><given-names>A.-M.</given-names></name>
<name><surname>Langeland</surname><given-names>M.</given-names></name>
<name><surname>Mongil</surname><given-names>C.M.</given-names></name>
<name><surname>Grondahl</surname><given-names>A.M.</given-names></name>
<name><surname>Teige</surname><given-names>J.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Canine Mammary Gland Tumours; a Histological Continuum from Benign to Malignant; Clinical and Histopathological Evidence</article-title><source>Vet. Comp. Oncol.</source><year>2009</year><volume>7</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5829.2009.00184.x</pub-id><pub-id pub-id-type="pmid">19691645</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00183"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sorenmo</surname><given-names>K.U.</given-names></name>
<name><surname>Shofer</surname><given-names>F.S.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Effect of Spaying and Timing of Spaying on Survival of Dogs with Mammary Carcinoma</article-title><source>J. Vet. Intern. Med.</source><year>2000</year><volume>14</volume><fpage>266</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1111/j.1939-1676.2000.tb01165.x</pub-id><pub-id pub-id-type="pmid">10830539</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00183"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sleeckx</surname><given-names>N.</given-names></name>
<name><surname>de Rooster</surname><given-names>H.</given-names></name>
<name><surname>Veldhuis Kroeze</surname><given-names>E.</given-names></name>
<name><surname>Van Ginneken</surname><given-names>C.</given-names></name>
<name><surname>Van Brantegem</surname><given-names>L.</given-names></name>
</person-group><article-title>Canine Mammary Tumours, an Overview</article-title><source>Reprod. Domest. Anim.</source><year>2011</year><volume>46</volume><fpage>1112</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0531.2011.01816.x</pub-id><pub-id pub-id-type="pmid">21645126</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00183"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borst</surname><given-names>P.</given-names></name>
<name><surname>Wessels</surname><given-names>L.</given-names></name>
</person-group><article-title>Do Predictive Signatures Really Predict Response to Cancer Chemotherapy?</article-title><source>Cell Cycle</source><year>2010</year><volume>9</volume><fpage>4836</fpage><lpage>4840</lpage><pub-id pub-id-type="doi">10.4161/cc.9.24.14326</pub-id><pub-id pub-id-type="pmid">21150277</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00183"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alsaihati</surname><given-names>B.A.</given-names></name>
<name><surname>Ho</surname><given-names>K.L.</given-names></name>
<name><surname>Watson</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Dobbin</surname><given-names>K.K.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
</person-group><article-title>Canine Tumor Mutational Burden Is Correlated with TP53 Mutation across Tumor Types and Breeds</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-24836-9</pub-id><pub-id pub-id-type="pmid">33397941</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00183"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inglebert</surname><given-names>M.</given-names></name>
<name><surname>Dettwiler</surname><given-names>M.</given-names></name>
<name><surname>Hahn</surname><given-names>K.</given-names></name>
<name><surname>Letko</surname><given-names>A.</given-names></name>
<name><surname>Drogemuller</surname><given-names>C.</given-names></name>
<name><surname>Doench</surname><given-names>J.</given-names></name>
<name><surname>Brown</surname><given-names>A.</given-names></name>
<name><surname>Memari</surname><given-names>Y.</given-names></name>
<name><surname>Davies</surname><given-names>H.R.</given-names></name>
<name><surname>Degasperi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>A Living Biobank of Canine Mammary Tumor Organoids as a Comparative Model for Human Breast Cancer</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-022-21706-2</pub-id><pub-id pub-id-type="pmid">34992227</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00183"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>T.-M.</given-names></name>
<name><surname>Yang</surname><given-names>I.S.</given-names></name>
<name><surname>Seung</surname><given-names>B.-J.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Ha</surname><given-names>Y.-J.</given-names></name>
<name><surname>Seo</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>K.-K.</given-names></name>
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
<name><surname>Cheong</surname><given-names>J.-H.</given-names></name>
<etal/>
</person-group><article-title>Cross-Species Oncogenic Signatures of Breast Cancer in Canine Mammary Tumors</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3616</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17458-0</pub-id><pub-id pub-id-type="pmid">32680987</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00183"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>B.</given-names></name>
<name><surname>Chin</surname><given-names>S.-F.</given-names></name>
<name><surname>Rueda</surname><given-names>O.M.</given-names></name>
<name><surname>Vollan</surname><given-names>H.-K.M.</given-names></name>
<name><surname>Provenzano</surname><given-names>E.</given-names></name>
<name><surname>Bardwell</surname><given-names>H.A.</given-names></name>
<name><surname>Pugh</surname><given-names>M.</given-names></name>
<name><surname>Jones</surname><given-names>L.</given-names></name>
<name><surname>Russell</surname><given-names>R.</given-names></name>
<name><surname>Sammut</surname><given-names>S.-J.</given-names></name>
<etal/>
</person-group><article-title>The Somatic Mutation Profiles of 2,433 Breast Cancers Refine Their Genomic and Transcriptomic Landscapes</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>11479</fpage><pub-id pub-id-type="doi">10.1038/ncomms11479</pub-id><pub-id pub-id-type="pmid">27161491</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00183"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nik-Zainal</surname><given-names>S.</given-names></name>
<name><surname>Davies</surname><given-names>H.</given-names></name>
<name><surname>Staaf</surname><given-names>J.</given-names></name>
<name><surname>Ramakrishna</surname><given-names>M.</given-names></name>
<name><surname>Glodzik</surname><given-names>D.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
<name><surname>Martincorena</surname><given-names>I.</given-names></name>
<name><surname>Alexandrov</surname><given-names>L.B.</given-names></name>
<name><surname>Martin</surname><given-names>S.</given-names></name>
<name><surname>Wedge</surname><given-names>D.C.</given-names></name>
<etal/>
</person-group><article-title>Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome Sequences</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature17676</pub-id><pub-id pub-id-type="pmid">27135926</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00183"><label>15.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Zappulli</surname><given-names>V.</given-names></name>
<name><surname>Kiupel</surname><given-names>M.</given-names></name>
</person-group><article-title>Surgical pathology of tumors of domestic animals</article-title><source>Surgical Pathology of Tumors of Domestic Animals: Mammary Tumors</source><publisher-name>Davis-Thompson DVM Foundation</publisher-name><publisher-loc>Baton Rouge, LA, USA</publisher-loc><year>2019</year><isbn>9781733749114</isbn></element-citation></ref><ref id="B16-vetsci-12-00183"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varallo</surname><given-names>G.</given-names></name>
<name><surname>Gelaleti</surname><given-names>G.</given-names></name>
<name><surname>Maschio-Signorini</surname><given-names>L.</given-names></name>
<name><surname>Moschetta</surname><given-names>M.</given-names></name>
<name><surname>Lopes</surname><given-names>J.</given-names></name>
<name><surname>De Nardi</surname><given-names>A.</given-names></name>
<name><surname>Tinucci-Costa</surname><given-names>M.</given-names></name>
<name><surname>Rocha</surname><given-names>R.</given-names></name>
<name><surname>de Campos Zuccari</surname><given-names>D.</given-names></name>
</person-group><article-title>Prognostic Phenotypic Classification for Canine Mammary Tumors</article-title><source>Oncol. Lett.</source><year>2019</year><volume>18</volume><fpage>6545</fpage><lpage>6553</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.11052</pub-id><pub-id pub-id-type="pmid">31807173</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00183"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pe&#x000f1;a</surname><given-names>L.</given-names></name>
<name><surname>Gama</surname><given-names>A.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>M.H.</given-names></name>
<name><surname>Abadie</surname><given-names>J.</given-names></name>
<name><surname>Benazzi</surname><given-names>C.</given-names></name>
<name><surname>Castagnaro</surname><given-names>M.</given-names></name>
<name><surname>D&#x000ed;ez</surname><given-names>L.</given-names></name>
<name><surname>G&#x000e4;rtner</surname><given-names>F.</given-names></name>
<name><surname>Hellm&#x000e9;n</surname><given-names>E.</given-names></name>
<name><surname>Kiupel</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Canine Mammary Tumors</article-title><source>Vet. Pathol.</source><year>2014</year><volume>51</volume><fpage>127</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1177/0300985813509388</pub-id><pub-id pub-id-type="pmid">24227007</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00183"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartwell</surname><given-names>L.H.</given-names></name>
<name><surname>Szankasi</surname><given-names>P.</given-names></name>
<name><surname>Roberts</surname><given-names>C.J.</given-names></name>
<name><surname>Murray</surname><given-names>A.W.</given-names></name>
<name><surname>Friend</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Integrating Genetic Approaches into the Discovery of Anticancer Drugs</article-title><source>Science</source><year>1997</year><volume>278</volume><fpage>1064</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1126/science.278.5340.1064</pub-id><pub-id pub-id-type="pmid">9353181</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00183"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hart</surname><given-names>T.</given-names></name>
<name><surname>Tong</surname><given-names>A.H.Y.</given-names></name>
<name><surname>Chan</surname><given-names>K.</given-names></name>
<name><surname>Van Leeuwen</surname><given-names>J.</given-names></name>
<name><surname>Seetharaman</surname><given-names>A.</given-names></name>
<name><surname>Aregger</surname><given-names>M.</given-names></name>
<name><surname>Chandrashekhar</surname><given-names>M.</given-names></name>
<name><surname>Hustedt</surname><given-names>N.</given-names></name>
<name><surname>Seth</surname><given-names>S.</given-names></name>
<name><surname>Noonan</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens</article-title><source>G3 Genes Genomes Genet.</source><year>2017</year><volume>7</volume><fpage>2719</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1534/g3.117.041277</pub-id></element-citation></ref><ref id="B20-vetsci-12-00183"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schuster</surname><given-names>A.</given-names></name>
<name><surname>Erasimus</surname><given-names>H.</given-names></name>
<name><surname>Fritah</surname><given-names>S.</given-names></name>
<name><surname>Nazarov</surname><given-names>P.V.</given-names></name>
<name><surname>van Dyck</surname><given-names>E.</given-names></name>
<name><surname>Niclou</surname><given-names>S.P.</given-names></name>
<name><surname>Golebiewska</surname><given-names>A.</given-names></name>
</person-group><article-title>RNAi/CRISPR Screens: From a Pool to a Valid Hit</article-title><source>Trends Biotechnol.</source><year>2019</year><volume>37</volume><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2018.08.002</pub-id><pub-id pub-id-type="pmid">30177380</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00183"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>C.</given-names></name>
<name><surname>Yuan</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>W.</given-names></name>
</person-group><article-title>High-Throughput Screening of a CRISPR/Cas9 Library for Functional Genomics in Human Cells</article-title><source>Nature</source><year>2014</year><volume>509</volume><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/nature13166</pub-id><pub-id pub-id-type="pmid">24717434</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00183"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Behan</surname><given-names>F.M.</given-names></name>
<name><surname>Iorio</surname><given-names>F.</given-names></name>
<name><surname>Picco</surname><given-names>G.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>E.</given-names></name>
<name><surname>Beaver</surname><given-names>C.M.</given-names></name>
<name><surname>Migliardi</surname><given-names>G.</given-names></name>
<name><surname>Santos</surname><given-names>R.</given-names></name>
<name><surname>Rao</surname><given-names>Y.</given-names></name>
<name><surname>Sassi</surname><given-names>F.</given-names></name>
<name><surname>Pinnelli</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Prioritization of Cancer Therapeutic Targets Using CRISPR&#x02013;Cas9 Screens</article-title><source>Nature</source><year>2019</year><volume>568</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1103-9</pub-id><pub-id pub-id-type="pmid">30971826</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00183"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ungricht</surname><given-names>R.</given-names></name>
<name><surname>Guibbal</surname><given-names>L.</given-names></name>
<name><surname>Lasbennes</surname><given-names>M.-C.</given-names></name>
<name><surname>Orsini</surname><given-names>V.</given-names></name>
<name><surname>Beibel</surname><given-names>M.</given-names></name>
<name><surname>Waldt</surname><given-names>A.</given-names></name>
<name><surname>Cuttat</surname><given-names>R.</given-names></name>
<name><surname>Carbone</surname><given-names>W.</given-names></name>
<name><surname>Basler</surname><given-names>A.</given-names></name>
<name><surname>Roma</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Genome-Wide Screening in Human Kidney Organoids Identifies Developmental and Disease-Related Aspects of Nephrogenesis</article-title><source>Cell Stem Cell</source><year>2022</year><volume>29</volume><fpage>160</fpage><lpage>175.e7</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.11.001</pub-id><pub-id pub-id-type="pmid">34847364</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00183"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerhards</surname><given-names>N.M.</given-names></name>
<name><surname>Rottenberg</surname><given-names>S.</given-names></name>
</person-group><article-title>New Tools for Old Drugs: Functional Genetic Screens to Optimize Current Chemotherapy</article-title><source>Drug Resist. Updates</source><year>2018</year><volume>36</volume><fpage>30</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.01.001</pub-id></element-citation></ref><ref id="B25-vetsci-12-00183"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michels</surname><given-names>B.E.</given-names></name>
<name><surname>Mosa</surname><given-names>M.H.</given-names></name>
<name><surname>Streibl</surname><given-names>B.I.</given-names></name>
<name><surname>Zhan</surname><given-names>T.</given-names></name>
<name><surname>Menche</surname><given-names>C.</given-names></name>
<name><surname>Abou-El-Ardat</surname><given-names>K.</given-names></name>
<name><surname>Darvishi</surname><given-names>T.</given-names></name>
<name><surname>Cz&#x00142;onka</surname><given-names>E.</given-names></name>
<name><surname>Wagner</surname><given-names>S.</given-names></name>
<name><surname>Winter</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids</article-title><source>Cell Stem Cell</source><year>2020</year><volume>26</volume><fpage>782</fpage><lpage>792.e7</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.04.003</pub-id><pub-id pub-id-type="pmid">32348727</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00183"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duarte</surname><given-names>A.A.</given-names></name>
<name><surname>Gogola</surname><given-names>E.</given-names></name>
<name><surname>Sachs</surname><given-names>N.</given-names></name>
<name><surname>Barazas</surname><given-names>M.</given-names></name>
<name><surname>Annunziato</surname><given-names>S.</given-names></name>
<name><surname>R De Ruiter</surname><given-names>J.</given-names></name>
<name><surname>Velds</surname><given-names>A.</given-names></name>
<name><surname>Blatter</surname><given-names>S.</given-names></name>
<name><surname>Houthuijzen</surname><given-names>J.M.</given-names></name>
<name><surname>Van De Ven</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>BRCA-Deficient Mouse Mammary Tumor Organoids to Study Cancer-Drug Resistance</article-title><source>Nat. Methods</source><year>2018</year><volume>15</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4535</pub-id><pub-id pub-id-type="pmid">29256493</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00183"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Francica</surname><given-names>P.</given-names></name>
<name><surname>Mutlu</surname><given-names>M.</given-names></name>
<name><surname>Blomen</surname><given-names>V.A.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.</given-names></name>
<name><surname>Nowicka</surname><given-names>Z.</given-names></name>
<name><surname>Trenner</surname><given-names>A.</given-names></name>
<name><surname>Gerhards</surname><given-names>N.M.</given-names></name>
<name><surname>Bouwman</surname><given-names>P.</given-names></name>
<name><surname>Stickel</surname><given-names>E.</given-names></name>
<name><surname>Hekkelman</surname><given-names>M.L.</given-names></name>
<etal/>
</person-group><article-title>Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-Homologous End Joining</article-title><source>Cell Rep.</source><year>2020</year><volume>32</volume><fpage>108068</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108068</pub-id><pub-id pub-id-type="pmid">32846126</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00183"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koo</surname><given-names>B.-K.</given-names></name>
<name><surname>Stange</surname><given-names>D.E.</given-names></name>
<name><surname>Sato</surname><given-names>T.</given-names></name>
<name><surname>Karthaus</surname><given-names>W.</given-names></name>
<name><surname>Farin</surname><given-names>H.F.</given-names></name>
<name><surname>Huch</surname><given-names>M.</given-names></name>
<name><surname>van Es</surname><given-names>J.H.</given-names></name>
<name><surname>Clevers</surname><given-names>H.</given-names></name>
</person-group><article-title>Controlled Gene Expression in Primary Lgr5 Organoid Cultures</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>81</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1802</pub-id></element-citation></ref><ref id="B29-vetsci-12-00183"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Xiao</surname><given-names>T.</given-names></name>
<name><surname>Cong</surname><given-names>L.</given-names></name>
<name><surname>Love</surname><given-names>M.I.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Irizarry</surname><given-names>R.A.</given-names></name>
<name><surname>Liu</surname><given-names>J.S.</given-names></name>
<name><surname>Brown</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>X.S.</given-names></name>
</person-group><article-title>MAGeCK Enables Robust Identification of Essential Genes from Genome-Scale CRISPR/Cas9 Knockout Screens</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00183"><label>30.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
</person-group><article-title>Fastp: An Ultra-Fast All-in-One FASTQ Preprocessor</article-title><source>Proceedings of the Bioinformatics</source><conf-loc>Oxford, UK</conf-loc><conf-date>1 September 2018</conf-date><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2018</year><volume>Volume 34</volume><fpage>i884</fpage><lpage>i890</lpage></element-citation></ref><ref id="B31-vetsci-12-00183"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pertea</surname><given-names>M.</given-names></name>
<name><surname>Pertea</surname><given-names>G.M.</given-names></name>
<name><surname>Antonescu</surname><given-names>C.M.</given-names></name>
<name><surname>Chang</surname><given-names>T.-C.</given-names></name>
<name><surname>Mendell</surname><given-names>J.T.</given-names></name>
<name><surname>Salzberg</surname><given-names>S.L.</given-names></name>
</person-group><article-title>StringTie Enables Improved Reconstruction of a Transcriptome from RNA-Seq Reads</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/nbt.3122</pub-id><pub-id pub-id-type="pmid">25690850</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00183"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>N.L.</given-names></name>
<name><surname>Pimentel</surname><given-names>H.</given-names></name>
<name><surname>Melsted</surname><given-names>P.</given-names></name>
<name><surname>Pachter</surname><given-names>L.</given-names></name>
</person-group><article-title>Near-Optimal Probabilistic RNA-Seq Quantification</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00183"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Love</surname><given-names>M.I.</given-names></name>
<name><surname>Huber</surname><given-names>W.</given-names></name>
<name><surname>Anders</surname><given-names>S.</given-names></name>
</person-group><article-title>Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00183"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doench</surname><given-names>J.G.</given-names></name>
<name><surname>Fusi</surname><given-names>N.</given-names></name>
<name><surname>Sullender</surname><given-names>M.</given-names></name>
<name><surname>Hegde</surname><given-names>M.</given-names></name>
<name><surname>Vaimberg</surname><given-names>E.W.</given-names></name>
<name><surname>Donovan</surname><given-names>K.F.</given-names></name>
<name><surname>Smith</surname><given-names>I.</given-names></name>
<name><surname>Tothova</surname><given-names>Z.</given-names></name>
<name><surname>Wilen</surname><given-names>C.</given-names></name>
<name><surname>Orchard</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Optimized SgRNA Design to Maximize Activity and Minimize Off-Target Effects of CRISPR-Cas9</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id>
</element-citation></ref><ref id="B35-vetsci-12-00183"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanson</surname><given-names>K.R.</given-names></name>
<name><surname>Hanna</surname><given-names>R.E.</given-names></name>
<name><surname>Hegde</surname><given-names>M.</given-names></name>
<name><surname>Donovan</surname><given-names>K.F.</given-names></name>
<name><surname>Strand</surname><given-names>C.</given-names></name>
<name><surname>Sullender</surname><given-names>M.E.</given-names></name>
<name><surname>Vaimberg</surname><given-names>E.W.</given-names></name>
<name><surname>Goodale</surname><given-names>A.</given-names></name>
<name><surname>Root</surname><given-names>D.E.</given-names></name>
<name><surname>Piccioni</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Optimized Libraries for CRISPR-Cas9 Genetic Screens with Multiple Modalities</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>5416</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-07901-8</pub-id><pub-id pub-id-type="pmid">30575746</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00183"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henser-Brownhill</surname><given-names>T.</given-names></name>
<name><surname>Monserrat</surname><given-names>J.</given-names></name>
<name><surname>Scaffidi</surname><given-names>P.</given-names></name>
</person-group><article-title>Generation of an Arrayed CRISPR-Cas9 Library Targeting Epigenetic Regulators: From High-Content Screens to in Vivo Assays</article-title><source>Epigenetics</source><year>2017</year><volume>12</volume><fpage>1065</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1080/15592294.2017.1395121</pub-id><pub-id pub-id-type="pmid">29327641</pub-id>
</element-citation></ref><ref id="B37-vetsci-12-00183"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>R.T.</given-names></name>
<name><surname>Guarecuco</surname><given-names>R.</given-names></name>
<name><surname>Gates</surname><given-names>L.A.</given-names></name>
<name><surname>Barrows</surname><given-names>D.</given-names></name>
<name><surname>Passarelli</surname><given-names>M.C.</given-names></name>
<name><surname>Carey</surname><given-names>B.</given-names></name>
<name><surname>Baudrier</surname><given-names>L.</given-names></name>
<name><surname>Jeewajee</surname><given-names>S.</given-names></name>
<name><surname>La</surname><given-names>K.</given-names></name>
<name><surname>Prizer</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase</article-title><source>Cell Metab.</source><year>2020</year><volume>31</volume><fpage>852</fpage><lpage>861.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.03.008</pub-id><pub-id pub-id-type="pmid">32268116</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00183"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gokirmak</surname><given-names>T.</given-names></name>
<name><surname>Sharp</surname><given-names>J.</given-names></name>
<name><surname>Revankar</surname><given-names>C.</given-names></name>
<name><surname>Piper</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Abstract LB-067: Identifying Novel and Druggable Targets in a Triple Negative Breast Cancer Cell Line Using the Invitrogen LentiArray Human Kinase CRISPR Library</article-title><source>Cancer Res.</source><year>2018</year><volume>78</volume><fpage>LB-067</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2018-LB-067</pub-id></element-citation></ref><ref id="B39-vetsci-12-00183"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>Lei</surname><given-names>X.Y.</given-names></name>
<name><surname>Larson</surname><given-names>J.D.</given-names></name>
<name><surname>McAlonis</surname><given-names>M.</given-names></name>
<name><surname>Ford</surname><given-names>K.</given-names></name>
<name><surname>McDonald</surname><given-names>D.</given-names></name>
<name><surname>Mach</surname><given-names>K.</given-names></name>
<name><surname>Rusert</surname><given-names>J.M.</given-names></name>
<name><surname>Wechsler-Reya</surname><given-names>R.J.</given-names></name>
<name><surname>Mali</surname><given-names>P.</given-names></name>
</person-group><article-title>Integrated Genome and Tissue Engineering Enables Screening of Cancer Vulnerabilities in Physiologically Relevant Perfusable Ex Vivo Cultures</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><elocation-id>121276</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121276</pub-id><pub-id pub-id-type="pmid">34890975</pub-id>
</element-citation></ref><ref id="B40-vetsci-12-00183"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>C.-T.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
</person-group><article-title>DEG 10, an Update of the Database of Essential Genes That Includes Both Protein-Coding Genes and Noncoding Genomic Elements: Table 1</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>D574</fpage><lpage>D580</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1131</pub-id><pub-id pub-id-type="pmid">24243843</pub-id>
</element-citation></ref><ref id="B41-vetsci-12-00183"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szklarczyk</surname><given-names>D.</given-names></name>
<name><surname>Gable</surname><given-names>A.L.</given-names></name>
<name><surname>Lyon</surname><given-names>D.</given-names></name>
<name><surname>Junge</surname><given-names>A.</given-names></name>
<name><surname>Wyder</surname><given-names>S.</given-names></name>
<name><surname>Huerta-Cepas</surname><given-names>J.</given-names></name>
<name><surname>Simonovic</surname><given-names>M.</given-names></name>
<name><surname>Doncheva</surname><given-names>N.T.</given-names></name>
<name><surname>Morris</surname><given-names>J.H.</given-names></name>
<name><surname>Bork</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>STRING V11: Protein&#x02013;Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id>
</element-citation></ref><ref id="B42-vetsci-12-00183"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanehisa</surname><given-names>M.</given-names></name>
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Kawashima</surname><given-names>M.</given-names></name>
<name><surname>Furumichi</surname><given-names>M.</given-names></name>
<name><surname>Tanabe</surname><given-names>M.</given-names></name>
</person-group><article-title>KEGG as a Reference Resource for Gene and Protein Annotation</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>D457</fpage><lpage>D462</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id><pub-id pub-id-type="pmid">26476454</pub-id>
</element-citation></ref><ref id="B43-vetsci-12-00183"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coussens</surname><given-names>L.M.</given-names></name>
<name><surname>Werb</surname><given-names>Z.</given-names></name>
</person-group><article-title>Inflammation and Cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/nature01322</pub-id><pub-id pub-id-type="pmid">12490959</pub-id>
</element-citation></ref><ref id="B44-vetsci-12-00183"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greten</surname><given-names>F.R.</given-names></name>
<name><surname>Grivennikov</surname><given-names>S.I.</given-names></name>
</person-group><article-title>Inflammation and Cancer: Triggers, Mechanisms, and Consequences</article-title><source>Immunity</source><year>2019</year><volume>51</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.025</pub-id><pub-id pub-id-type="pmid">31315034</pub-id>
</element-citation></ref><ref id="B45-vetsci-12-00183"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tadesse</surname><given-names>S.</given-names></name>
<name><surname>Anshabo</surname><given-names>A.T.</given-names></name>
<name><surname>Portman</surname><given-names>N.</given-names></name>
<name><surname>Lim</surname><given-names>E.</given-names></name>
<name><surname>Tilley</surname><given-names>W.</given-names></name>
<name><surname>Caldon</surname><given-names>C.E.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Targeting CDK2 in Cancer: Challenges and Opportunities for Therapy</article-title><source>Drug Discov. Today</source><year>2020</year><volume>25</volume><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.12.001</pub-id><pub-id pub-id-type="pmid">31839441</pub-id>
</element-citation></ref><ref id="B46-vetsci-12-00183"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Satyanarayana</surname><given-names>A.</given-names></name>
<name><surname>Kaldis</surname><given-names>P.</given-names></name>
</person-group><article-title>Mammalian Cell-Cycle Regulation: Several Cdks, Numerous Cyclins and Diverse Compensatory Mechanisms</article-title><source>Oncogene</source><year>2009</year><volume>28</volume><fpage>2925</fpage><lpage>2939</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.170</pub-id><pub-id pub-id-type="pmid">19561645</pub-id>
</element-citation></ref><ref id="B47-vetsci-12-00183"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freeman-Cook</surname><given-names>K.D.</given-names></name>
<name><surname>Hoffman</surname><given-names>R.L.</given-names></name>
<name><surname>Behenna</surname><given-names>D.C.</given-names></name>
<name><surname>Boras</surname><given-names>B.</given-names></name>
<name><surname>Carelli</surname><given-names>J.</given-names></name>
<name><surname>Diehl</surname><given-names>W.</given-names></name>
<name><surname>Ferre</surname><given-names>R.A.</given-names></name>
<name><surname>He</surname><given-names>Y.A.</given-names></name>
<name><surname>Hui</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>9056</fpage><lpage>9077</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00159</pub-id><pub-id pub-id-type="pmid">34110834</pub-id>
</element-citation></ref><ref id="B48-vetsci-12-00183"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freeman-Cook</surname><given-names>K.</given-names></name>
<name><surname>Hoffman</surname><given-names>R.L.</given-names></name>
<name><surname>Miller</surname><given-names>N.</given-names></name>
<name><surname>Almaden</surname><given-names>J.</given-names></name>
<name><surname>Chionis</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Eisele</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Huser</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Expanding Control of the Tumor Cell Cycle with a CDK2/4/6 Inhibitor</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1404</fpage><lpage>1421.e11</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.08.009</pub-id><pub-id pub-id-type="pmid">34520734</pub-id>
</element-citation></ref><ref id="B49-vetsci-12-00183"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pommier</surname><given-names>Y.</given-names></name>
<name><surname>Leo</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Marchand</surname><given-names>C.</given-names></name>
</person-group><article-title>DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs</article-title><source>Chem. Biol.</source><year>2010</year><volume>17</volume><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2010.04.012</pub-id><pub-id pub-id-type="pmid">20534341</pub-id>
</element-citation></ref><ref id="B50-vetsci-12-00183"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Libouban</surname><given-names>M.A.A.</given-names></name>
<name><surname>de Roos</surname><given-names>J.A.D.M.</given-names></name>
<name><surname>Uitdehaag</surname><given-names>J.C.M.</given-names></name>
<name><surname>Willemsen-Seegers</surname><given-names>N.</given-names></name>
<name><surname>Mainardi</surname><given-names>S.</given-names></name>
<name><surname>Dylus</surname><given-names>J.</given-names></name>
<name><surname>de Man</surname><given-names>J.</given-names></name>
<name><surname>Tops</surname><given-names>B.</given-names></name>
<name><surname>Meijerink</surname><given-names>J.P.P.</given-names></name>
<name><surname>Storchov&#x000e1;</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Stable Aneuploid Tumors Cells Are More Sensitive to TTK Inhibition than Chromosomally Unstable Cell Lines</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>38309</fpage><lpage>38325</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16213</pub-id><pub-id pub-id-type="pmid">28415765</pub-id>
</element-citation></ref><ref id="B51-vetsci-12-00183"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Alise</surname><given-names>A.M.</given-names></name>
<name><surname>Amabile</surname><given-names>G.</given-names></name>
<name><surname>Iovino</surname><given-names>M.</given-names></name>
<name><surname>Di Giorgio</surname><given-names>F.P.</given-names></name>
<name><surname>Bartiromo</surname><given-names>M.</given-names></name>
<name><surname>Sessa</surname><given-names>F.</given-names></name>
<name><surname>Villa</surname><given-names>F.</given-names></name>
<name><surname>Musacchio</surname><given-names>A.</given-names></name>
<name><surname>Cortese</surname><given-names>R.</given-names></name>
</person-group><article-title>Reversine, a Novel Aurora Kinases Inhibitor, Inhibits Colony Formation of Human Acute Myeloid Leukemia Cells</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><fpage>1140</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-2051</pub-id><pub-id pub-id-type="pmid">18483302</pub-id>
</element-citation></ref><ref id="B52-vetsci-12-00183"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Augello</surname><given-names>G.</given-names></name>
<name><surname>Emma</surname><given-names>M.R.</given-names></name>
<name><surname>Cusimano</surname><given-names>A.</given-names></name>
<name><surname>Azzolina</surname><given-names>A.</given-names></name>
<name><surname>Mongiov&#x000ec;</surname><given-names>S.</given-names></name>
<name><surname>Puleio</surname><given-names>R.</given-names></name>
<name><surname>Cassata</surname><given-names>G.</given-names></name>
<name><surname>Gulino</surname><given-names>A.</given-names></name>
<name><surname>Belmonte</surname><given-names>B.</given-names></name>
<name><surname>Gramignoli</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Targeting HSP90 with the Small Molecule Inhibitor AUY922 (Luminespib) as a Treatment Strategy against Hepatocellular Carcinoma</article-title><source>Int. J. Cancer</source><year>2019</year><volume>144</volume><fpage>2613</fpage><lpage>2624</lpage><pub-id pub-id-type="doi">10.1002/ijc.31963</pub-id><pub-id pub-id-type="pmid">30488605</pub-id>
</element-citation></ref><ref id="B53-vetsci-12-00183"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antolin</surname><given-names>A.A.</given-names></name>
<name><surname>Clarke</surname><given-names>P.A.</given-names></name>
<name><surname>Collins</surname><given-names>I.</given-names></name>
<name><surname>Workman</surname><given-names>P.</given-names></name>
<name><surname>Al-Lazikani</surname><given-names>B.</given-names></name>
</person-group><article-title>Evolution of Kinase Polypharmacology across HSP90 Drug Discovery</article-title><source>Cell Chem. Biol.</source><year>2021</year><volume>28</volume><fpage>1433</fpage><lpage>1445.e3</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2021.05.004</pub-id><pub-id pub-id-type="pmid">34077750</pub-id>
</element-citation></ref><ref id="B54-vetsci-12-00183"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matano</surname><given-names>M.</given-names></name>
<name><surname>Date</surname><given-names>S.</given-names></name>
<name><surname>Shimokawa</surname><given-names>M.</given-names></name>
<name><surname>Takano</surname><given-names>A.</given-names></name>
<name><surname>Fujii</surname><given-names>M.</given-names></name>
<name><surname>Ohta</surname><given-names>Y.</given-names></name>
<name><surname>Watanabe</surname><given-names>T.</given-names></name>
<name><surname>Kanai</surname><given-names>T.</given-names></name>
<name><surname>Sato</surname><given-names>T.</given-names></name>
</person-group><article-title>Modeling Colorectal Cancer Using CRISPR-Cas9-Mediated Engineering of Human Intestinal Organoids</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nm.3802</pub-id><pub-id pub-id-type="pmid">25706875</pub-id>
</element-citation></ref><ref id="B55-vetsci-12-00183"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drost</surname><given-names>J.</given-names></name>
<name><surname>van Boxtel</surname><given-names>R.</given-names></name>
<name><surname>Blokzijl</surname><given-names>F.</given-names></name>
<name><surname>Mizutani</surname><given-names>T.</given-names></name>
<name><surname>Sasaki</surname><given-names>N.</given-names></name>
<name><surname>Sasselli</surname><given-names>V.</given-names></name>
<name><surname>de Ligt</surname><given-names>J.</given-names></name>
<name><surname>Behjati</surname><given-names>S.</given-names></name>
<name><surname>Grolleman</surname><given-names>J.E.</given-names></name>
<name><surname>van Wezel</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Use of CRISPR-Modified Human Stem Cell Organoids to Study the Origin of Mutational Signatures in Cancer</article-title><source>Science</source><year>2017</year><volume>358</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1126/science.aao3130</pub-id><pub-id pub-id-type="pmid">28912133</pub-id>
</element-citation></ref><ref id="B56-vetsci-12-00183"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malumbres</surname><given-names>M.</given-names></name>
</person-group><article-title>Cyclin-Dependent Kinases</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/gb4184</pub-id><pub-id pub-id-type="pmid">25180339</pub-id>
</element-citation></ref><ref id="B57-vetsci-12-00183"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>G.K.</given-names></name>
<name><surname>Shah</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Targeting the Cell Cycle: A New Approach to Cancer Therapy</article-title><source>J. Clin. Oncol.</source><year>2005</year><volume>23</volume><fpage>9408</fpage><lpage>9421</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.01.5594</pub-id><pub-id pub-id-type="pmid">16361640</pub-id>
</element-citation></ref><ref id="B58-vetsci-12-00183"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Finn</surname><given-names>R.S.</given-names></name>
<name><surname>Martin</surname><given-names>M.</given-names></name>
<name><surname>Rugo</surname><given-names>H.S.</given-names></name>
<name><surname>Jones</surname><given-names>S.</given-names></name>
<name><surname>Im</surname><given-names>S.-A.</given-names></name>
<name><surname>Gelmon</surname><given-names>K.</given-names></name>
<name><surname>Harbeck</surname><given-names>N.</given-names></name>
<name><surname>Lipatov</surname><given-names>O.N.</given-names></name>
<name><surname>Walshe</surname><given-names>J.M.</given-names></name>
<name><surname>Moulder</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Palbociclib and Letrozole in Advanced Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1925</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607303</pub-id><pub-id pub-id-type="pmid">27959613</pub-id>
</element-citation></ref><ref id="B59-vetsci-12-00183"><label>59.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Pfizer</collab>
</person-group><source>Phase 1/2a Dose Escalation and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacody-namics and Anti-Tumor Activity of Pf-06873600 as a Single Agent and in Combination with Endocrine Therapy</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2022</year></element-citation></ref><ref id="B60-vetsci-12-00183"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenblum</surname><given-names>D.</given-names></name>
<name><surname>Gutkin</surname><given-names>A.</given-names></name>
<name><surname>Dammes</surname><given-names>N.</given-names></name>
<name><surname>Peer</surname><given-names>D.</given-names></name>
</person-group><article-title>Progress and Challenges towards CRISPR/Cas Clinical Translation</article-title><source>Adv. Drug Deliv. Rev.</source><year>2020</year><volume>154&#x02013;155</volume><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.07.004</pub-id></element-citation></ref><ref id="B61-vetsci-12-00183"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanker</surname><given-names>A.B.</given-names></name>
<name><surname>Chatterjee</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Ye</surname><given-names>D.</given-names></name>
<name><surname>Sudhan</surname><given-names>D.R.</given-names></name>
<name><surname>Larsen</surname><given-names>B.M.</given-names></name>
<name><surname>Smith</surname><given-names>L.C.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Kandagatla</surname><given-names>V.</given-names></name>
<name><surname>Majmudar</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Abstract PD2-01: A Platform of CDK4/6 Inhibitor-Resistant Patient-Derived Breast Cancer Organoids Illuminates Mechanisms of Resistance and Therapeutic Vulnerabilities</article-title><source>Cancer Res.</source><year>2022</year><volume>82</volume><fpage>PD2-01</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.SABCS21-PD2-01</pub-id></element-citation></ref><ref id="B62-vetsci-12-00183"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xavier</surname><given-names>P.L.P.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>S.</given-names></name>
<name><surname>Fukumasu</surname><given-names>H.</given-names></name>
</person-group><article-title>Epigenetic Mechanisms in Canine Cancer</article-title><source>Front. Oncol.</source><year>2020</year><volume>10</volume><elocation-id>591843</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.591843</pub-id><pub-id pub-id-type="pmid">33194754</pub-id>
</element-citation></ref><ref id="B63-vetsci-12-00183"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>da Costa Ferreira</surname><given-names>V.</given-names></name>
<name><surname>Pinheiro</surname><given-names>D.d.R.</given-names></name>
<name><surname>de Sousa</surname><given-names>R.M.</given-names></name>
<name><surname>de Aguirra</surname><given-names>L.R.V.M.</given-names></name>
<name><surname>Pereira</surname><given-names>W.L.A.</given-names></name>
<name><surname>Burbano</surname><given-names>R.M.R.</given-names></name>
<name><surname>Borges</surname><given-names>B.d.N.</given-names></name>
</person-group><article-title>Methylation Pattern and Mutational Status of BRCA1 in Canine Mammary Tumors in a Brazilian Population</article-title><source>Comp. Clin. Path</source><year>2019</year><volume>28</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s00580-018-2833-z</pub-id></element-citation></ref><ref id="B64-vetsci-12-00183"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>D.</given-names></name>
</person-group><article-title>Roles of DNA Mutation in the Coding Region and DNA Methylation in the 5&#x02032; Flanking Region of BRCA1 in Canine Mammary Tumors</article-title><source>J. Vet. Med. Sci.</source><year>2016</year><volume>78</volume><fpage>943</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1292/jvms.15-0557</pub-id><pub-id pub-id-type="pmid">26888582</pub-id>
</element-citation></ref><ref id="B65-vetsci-12-00183"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brand&#x000e3;o</surname><given-names>Y.d.O.</given-names></name>
<name><surname>Toledo</surname><given-names>M.B.</given-names></name>
<name><surname>Chequin</surname><given-names>A.</given-names></name>
<name><surname>Cristo</surname><given-names>T.G.</given-names></name>
<name><surname>Sousa</surname><given-names>R.S.</given-names></name>
<name><surname>Ramos</surname><given-names>E.A.S.</given-names></name>
<name><surname>Klassen</surname><given-names>G.</given-names></name>
</person-group><article-title>DNA Methylation Status of the Estrogen Receptor &#x003b1; Gene in Canine Mammary Tumors</article-title><source>Vet. Pathol.</source><year>2018</year><volume>55</volume><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1177/0300985818763711</pub-id><pub-id pub-id-type="pmid">29566609</pub-id>
</element-citation></ref><ref id="B66-vetsci-12-00183"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>S.-J.</given-names></name>
<name><surname>Lee</surname><given-names>K.-H.</given-names></name>
<name><surname>Nam</surname><given-names>A.-R.</given-names></name>
<name><surname>Cho</surname><given-names>J.-Y.</given-names></name>
</person-group><article-title>Genome-Wide Methylation Profiling in Canine Mammary Tumor Reveals MiRNA Candidates Associated with Human Breast Cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1466</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11101466</pub-id><pub-id pub-id-type="pmid">31569550</pub-id>
</element-citation></ref><ref id="B67-vetsci-12-00183"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>H.J.</given-names></name>
<name><surname>Jang</surname><given-names>S.</given-names></name>
<name><surname>Ryu</surname><given-names>J.E.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.B.</given-names></name>
<name><surname>Ahn</surname><given-names>W.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Gong</surname><given-names>G.Y.</given-names></name>
<etal/>
</person-group><article-title>Significance of EZH2 Expression in Canine Mammary Tumors</article-title><source>BMC Vet. Res.</source><year>2016</year><volume>12</volume><elocation-id>164</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-016-0789-2</pub-id><pub-id pub-id-type="pmid">27502594</pub-id>
</element-citation></ref><ref id="B68-vetsci-12-00183"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Xiong</surname><given-names>H.</given-names></name>
<name><surname>Ellis</surname><given-names>A.E.</given-names></name>
<name><surname>Northrup</surname><given-names>N.C.</given-names></name>
<name><surname>Rodriguez</surname><given-names>C.O.</given-names></name>
<name><surname>O&#x02019;Regan</surname><given-names>R.M.</given-names></name>
<name><surname>Dalton</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
</person-group><article-title>Molecular Homology and Difference between Spontaneous Canine Mammary Cancer and Human Breast Cancer</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>5045</fpage><lpage>5056</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0392</pub-id><pub-id pub-id-type="pmid">25082814</pub-id>
</element-citation></ref><ref id="B69-vetsci-12-00183"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boggs</surname><given-names>R.M.</given-names></name>
<name><surname>Wright</surname><given-names>Z.M.</given-names></name>
<name><surname>Stickney</surname><given-names>M.J.</given-names></name>
<name><surname>Porter</surname><given-names>W.W.</given-names></name>
<name><surname>Murphy</surname><given-names>K.E.</given-names></name>
</person-group><article-title>MicroRNA Expression in Canine Mammary Cancer</article-title><source>Mamm. Genome</source><year>2008</year><volume>19</volume><fpage>561</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1007/s00335-008-9128-7</pub-id><pub-id pub-id-type="pmid">18665421</pub-id>
</element-citation></ref><ref id="B70-vetsci-12-00183"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bulkowska</surname><given-names>M.</given-names></name>
<name><surname>Rybicka</surname><given-names>A.</given-names></name>
<name><surname>Senses</surname><given-names>K.M.</given-names></name>
<name><surname>Ulewicz</surname><given-names>K.</given-names></name>
<name><surname>Witt</surname><given-names>K.</given-names></name>
<name><surname>Szymanska</surname><given-names>J.</given-names></name>
<name><surname>Taciak</surname><given-names>B.</given-names></name>
<name><surname>Klopfleisch</surname><given-names>R.</given-names></name>
<name><surname>Hellm&#x000e9;n</surname><given-names>E.</given-names></name>
<name><surname>Dolka</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA Expression Patterns in Canine Mammary Cancer Show Significant Differences between Metastatic and Non-Metastatic Tumours</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>728</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3751-1</pub-id><pub-id pub-id-type="pmid">29115935</pub-id>
</element-citation></ref><ref id="B71-vetsci-12-00183"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fish</surname><given-names>E.J.</given-names></name>
<name><surname>Irizarry</surname><given-names>K.J.</given-names></name>
<name><surname>DeInnocentes</surname><given-names>P.</given-names></name>
<name><surname>Ellis</surname><given-names>C.J.</given-names></name>
<name><surname>Prasad</surname><given-names>N.</given-names></name>
<name><surname>Moss</surname><given-names>A.G.</given-names></name>
<name><surname>Curt Bird</surname><given-names>R.</given-names></name>
</person-group><article-title>Malignant Canine Mammary Epithelial Cells Shed Exosomes Containing Differentially Expressed MicroRNA That Regulate Oncogenic Networks</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1186/s12885-018-4750-6</pub-id><pub-id pub-id-type="pmid">29291726</pub-id>
</element-citation></ref><ref id="B72-vetsci-12-00183"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>R.G.</given-names></name>
<name><surname>Chambers</surname><given-names>A.C.</given-names></name>
<name><surname>Legge</surname><given-names>D.N.</given-names></name>
<name><surname>Coles</surname><given-names>S.J.</given-names></name>
<name><surname>Greenhough</surname><given-names>A.</given-names></name>
<name><surname>Williams</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Optimized Delivery of SiRNA into 3D Tumor Spheroid Cultures in Situ</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>7952</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26253-3</pub-id><pub-id pub-id-type="pmid">29785035</pub-id>
</element-citation></ref><ref id="B73-vetsci-12-00183"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nadauld</surname><given-names>L.D.</given-names></name>
<name><surname>Garcia</surname><given-names>S.</given-names></name>
<name><surname>Natsoulis</surname><given-names>G.</given-names></name>
<name><surname>Bell</surname><given-names>J.M.</given-names></name>
<name><surname>Miotke</surname><given-names>L.</given-names></name>
<name><surname>Hopmans</surname><given-names>E.S.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Pai</surname><given-names>R.K.</given-names></name>
<name><surname>Palm</surname><given-names>C.</given-names></name>
<name><surname>Regan</surname><given-names>J.F.</given-names></name>
<etal/>
</person-group><article-title>Metastatic Tumor Evolution and Organoid Modeling Implicate TGFBR2as a Cancer Driver in Diffuse Gastric Cancer</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><elocation-id>428</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0428-9</pub-id><pub-id pub-id-type="pmid">25315765</pub-id>
</element-citation></ref><ref id="B74-vetsci-12-00183"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menche</surname><given-names>C.</given-names></name>
<name><surname>Farin</surname><given-names>H.F.</given-names></name>
</person-group><article-title>Strategies for Genetic Manipulation of Adult Stem Cell-Derived Organoids</article-title><source>Exp. Mol. Med.</source><year>2021</year><volume>53</volume><fpage>1483</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00609-8</pub-id><pub-id pub-id-type="pmid">34663937</pub-id>
</element-citation></ref><ref id="B75-vetsci-12-00183"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>D.</given-names></name>
<name><surname>Evans</surname><given-names>L.</given-names></name>
<name><surname>Perrone</surname><given-names>F.</given-names></name>
<name><surname>Sokleva</surname><given-names>V.</given-names></name>
<name><surname>Lim</surname><given-names>K.</given-names></name>
<name><surname>Rezakhani</surname><given-names>S.</given-names></name>
<name><surname>Lutolf</surname><given-names>M.</given-names></name>
<name><surname>Zilbauer</surname><given-names>M.</given-names></name>
<name><surname>Rawlins</surname><given-names>E.L.</given-names></name>
</person-group><article-title>A Functional Genetic Toolbox for Human Tissue-Derived Organoids</article-title><source>Elife</source><year>2021</year><volume>10</volume><fpage>e67886</fpage><pub-id pub-id-type="doi">10.7554/eLife.67886</pub-id><pub-id pub-id-type="pmid">34612202</pub-id>
</element-citation></ref><ref id="B76-vetsci-12-00183"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andersson-Rolf</surname><given-names>A.</given-names></name>
<name><surname>Mustata</surname><given-names>R.C.</given-names></name>
<name><surname>Merenda</surname><given-names>A.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Perera</surname><given-names>S.</given-names></name>
<name><surname>Grego</surname><given-names>T.</given-names></name>
<name><surname>Andrews</surname><given-names>K.</given-names></name>
<name><surname>Tremble</surname><given-names>K.</given-names></name>
<name><surname>Silva</surname><given-names>J.C.R.</given-names></name>
<name><surname>Fink</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>One-Step Generation of Conditional and Reversible Gene Knockouts</article-title><source>Nat. Methods</source><year>2017</year><volume>14</volume><fpage>287</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4156</pub-id><pub-id pub-id-type="pmid">28135257</pub-id>
</element-citation></ref><ref id="B77-vetsci-12-00183"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Natsume</surname><given-names>T.</given-names></name>
<name><surname>Kiyomitsu</surname><given-names>T.</given-names></name>
<name><surname>Saga</surname><given-names>Y.</given-names></name>
<name><surname>Kanemaki</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Rapid Protein Depletion in Human Cells by Auxin-Inducible Degron Tagging with Short Homology Donors</article-title><source>Cell Rep.</source><year>2016</year><volume>15</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.03.001</pub-id><pub-id pub-id-type="pmid">27052166</pub-id>
</element-citation></ref><ref id="B78-vetsci-12-00183"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishimura</surname><given-names>K.</given-names></name>
<name><surname>Fukagawa</surname><given-names>T.</given-names></name>
<name><surname>Takisawa</surname><given-names>H.</given-names></name>
<name><surname>Kakimoto</surname><given-names>T.</given-names></name>
<name><surname>Kanemaki</surname><given-names>M.</given-names></name>
</person-group><article-title>An Auxin-Based Degron System for the Rapid Depletion of Proteins in Nonplant Cells</article-title><source>Nat. Methods</source><year>2009</year><volume>6</volume><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1401</pub-id><pub-id pub-id-type="pmid">19915560</pub-id>
</element-citation></ref><ref id="B79-vetsci-12-00183"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sachs</surname><given-names>N.</given-names></name>
<name><surname>de Ligt</surname><given-names>J.</given-names></name>
<name><surname>Kopper</surname><given-names>O.</given-names></name>
<name><surname>Gogola</surname><given-names>E.</given-names></name>
<name><surname>Bounova</surname><given-names>G.</given-names></name>
<name><surname>Weeber</surname><given-names>F.</given-names></name>
<name><surname>Balgobind</surname><given-names>A.V.</given-names></name>
<name><surname>Wind</surname><given-names>K.</given-names></name>
<name><surname>Gracanin</surname><given-names>A.</given-names></name>
<name><surname>Begthel</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>373</fpage><lpage>386.e10</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.010</pub-id><pub-id pub-id-type="pmid">29224780</pub-id>
</element-citation></ref><ref id="B80-vetsci-12-00183"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marx</surname><given-names>V.</given-names></name>
</person-group><article-title>Method of the Year: Spatially Resolved Transcriptomics</article-title><source>Nat. Methods</source><year>2021</year><volume>18</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-01033-y</pub-id><pub-id pub-id-type="pmid">33408395</pub-id>
</element-citation></ref><ref id="B81-vetsci-12-00183"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>C.</given-names></name>
<name><surname>Hong</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Bo</surname><given-names>X.</given-names></name>
</person-group><article-title>New Insights on Human Essential Genes Based on Integrated Analysis and the Construction of the HEGIAP Web-Based Platform</article-title><source>Brief. Bioinform.</source><year>2019</year><volume>21</volume><fpage>1397</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1093/bib/bbz072</pub-id></element-citation></ref><ref id="B82-vetsci-12-00183"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>Fu</surname><given-names>X.</given-names></name>
<name><surname>Si</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
</person-group><article-title>Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis</article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><elocation-id>1245</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2019.01245</pub-id><pub-id pub-id-type="pmid">31867042</pub-id>
</element-citation></ref><ref id="B83-vetsci-12-00183"><label>83.</label><element-citation publication-type="gov"><article-title>The Cancer Genome Atlas Program&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/tcga" ext-link-type="uri">https://www.cancer.gov/tcga</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-09-22">(accessed on 22 September 2022)</date-in-citation></element-citation></ref><ref id="B84-vetsci-12-00183"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Kang</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>W98</fpage><lpage>W102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmid">28407145</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="vetsci-12-00183-t002"><object-id pub-id-type="pii">vetsci-12-00183-t002_Table 2</object-id><label>Table 2</label><caption><p>Hits essential in ORG-63-C but dispensable in ORG-63-N (druggable screen).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_C</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_C</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSP90AA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heat shock protein HSP 90-alpha</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.70337</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18138</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02346</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.547</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FANCD2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fanconi anemia group D2 protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.603</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.22887</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04947</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.1426</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDK2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin-dependent kinase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53595</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.27009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.039806</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.4028</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TOP2B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA topoisomerase 2-beta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39481</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.0917</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0087646</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.5298</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPTOR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulatory-associated protein of mTOR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39167</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.45626</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.048055</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.0535</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCL2L1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bcl-2-like protein 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31849</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.26447</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013289</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.2187</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MYBL1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myb proto-oncogene like 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31416</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.5715</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024879</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.6852</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TTK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serine/threonine-protein kinase ttk/mps1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28795</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.61574</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013661</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.584</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FANCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fanconi anemia group C protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24945</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.54887</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0073124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9841</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">POLE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA polymerase &#x003b5; catalytic subunit A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24504</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.27922</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013083</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.3574</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDK12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyclin-dependent kinase 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23879</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.16167</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.008662</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9851</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMPS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMP synthase [glutamine-hydrolyzing]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23684</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.25904</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035056</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.4074</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCND3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G1/S-specific cyclin-D3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.86676</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017937</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.3585</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USP5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ubiquitin carboxyl-terminal hydrolase 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16569</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.87191</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023271</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.2658</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NFKBIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NF-kappa-B inhibitor alpha</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14329</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.99465</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0078846</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.0144</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PI4KB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphatidylinositol 4-kinase beta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10617</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.86682</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.036475</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.4132</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FANCE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fanconi anemia group E protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09315</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.67103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.026213</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.027</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00183-t003"><object-id pub-id-type="pii">vetsci-12-00183-t003_Table 3</object-id><label>Table 3</label><caption><p>MAGeCK screen results for CDK2, 4 and 6.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Library</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_N</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value_C</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">lfc_C</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" colspan="1">CP1736</td><td align="center" valign="middle" rowspan="1" colspan="1">CDK2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53595</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.27009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039806</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.4028</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CDK4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92691</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28251</td><td align="center" valign="middle" rowspan="1" colspan="1">0.16707</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.84773</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CDK6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.10149</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.1315</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0024321</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.6764</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP1737</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDK2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.74951</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.3541</td></tr></tbody></table></table-wrap></floats-group></article>